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The co-occurrence of psychotic symptoms and Alzheimer’s disease (AD) is a devastating 
phenotype that affects around 50% of individuals with AD. We hypothesized that distinct 
interactions between brain structures and genetic variants in dopaminergic, cholinergic and 
glutamatergic neurotransmitter systems may be associated with the presence of hallucinations 
and delusions in AD. Using the Alzheimer’s Disease Neuroimaging Initiative, we identified 
participants that presented with symptoms of delusions, hallucinations, or both symptoms. 
PLS-CA was used to identify differences in patterns of interactions between 15 single 
nucleotide polymorphisms and 82 neuroanatomical regions of interest between AD patients 
endorsing symptoms of delusions, hallucinations, and matched AD controls. Binary logistic 
regression analysis was used to cross-validate identified neuroanatomical differences. Results 
provide preliminary evidence that genetic variants in the glutamatergic system, along with 
regional brain changes, may uniquely identify those with hallucinations. A trend towards 
significance was also found which suggests that atrophy to the frontal lobe coupled with 
preservation of temporal lobe structures may be associated with symptoms of delusions in 
patients with AD. Overall, results provide evidence of a unique signature of neuroimaging 
and genetic interactions which may be associated with the presence of different psychotic 




Alzheimer’s disease, hallucinations, delusions, psychosis, single nucleotide polymorphisms, 
cholinergic system, dopaminergic system, glutamatergic system, neurotransmitters, Magnetic 






All data for this study was obtained from the Alzheimer’s Disease Neuroimaging Initiative. I 
completed all aspects of data cleaning, extraction, analysis, and thesis writing with feedback 
from Dr. Elizabeth Finger. I received assistance with data analysis and preprocessing from 
Derek Beaton and Andrew Robertson. All R scripts used for the PLS-CA were created by 
Derek Beaton and Andrew Robertson. GWAS data was preprocessed and imputed by the lab 






This project would not have been possible without the support, mentorship, and continued guidance 
that I received from the many people that I had the privilege to work with and learn from during my 
Master’s degree. I extend my sincerest gratitude to you all. 
 
To my supervisor, Dr. Elizabeth Finger: There are no words to express how grateful I am for all your 
guidance and mentorship. Thank you for believing in me and my ability to achieve all the goals that I 
set out for myself. From you, I have learned what it means to be an incredible leader, a scientist, and a 
clinician. You have instilled within me a passion for neuroscience and research. Thank you for 
sharing your expertise, encouraging me to think critically, and motivating me to never stop pursing 
the endless avenues of scientific inquiry. 
 
To my committee members: Dr. Palaniyappan and Dr. Pasternak, thank you both for sharing your 
time and expertise, and for providing me with valuable feedback during our advisory committee 
meetings.  
 
To all our collaborators: Derek Beaton, Andrew Robertson, Sejal Patel, Dr. Mario Masellis – thank 
you for your patience and willingness to take the time to teach me about different statistical 
techniques and genetic analysis. Additionally, thank you for your continued guidance throughout this 
project. 
 
To my lab members, past and present: Kristy Coleman, Chloe Stewart, Tamara Tavares, Mathura 
Thiyagarajah, Mika Ohtsuka, Eric Mitchell, Katie Helou, Carolina Silveira, Tommy Li, Sarah Jesso, 
Koula Pantazopoulos, Rokhsana Mortuza – thank you all for sharing in my happiness, for lifting me 
up, and for providing me with valuable advice and suggestions. I’m truly grateful to have met each 
and every one of you. And of course, thank you for always listening to my practice talks and 
presentations (even when you had heard it many times before).  
 
To my family and friends: Thank you for your continuous encouragement and unwavering support 
over the past two years (and throughout my life). Thank you for being there for me, believing in me, 
and for always keeping me grounded. 
 
Finally, thank you to all the participants who volunteered their time to be a part of the Alzheimer’s 
Disease Neuroimaging Initiative. None of this research would have been possible without your 
valuable contributions to the research community. Furthermore, thank you to the funding sources that 





Table of Contents 
Abstract ............................................................................................................................... ii 
Co-Authorship Statement ................................................................................................... iii 
Acknowledgments .............................................................................................................. iv 
Table of Contents ................................................................................................................ v 
List of Tables ................................................................................................................... viii 
List of Figures ..................................................................................................................... x 
List of Abbreviations ......................................................................................................... xi 
Chapter 1 ............................................................................................................................. 1 
1 Literature Review ........................................................................................................... 1 
1.1 Alzheimer’s Disease ............................................................................................... 2 
1.1.1 Stages of Cognitive Impairment and Progression to Alzheimer’s Disease ... 2 
1.1.2 Neuropathology of Alzheimer’s disease. ....................................................... 4 
1.1.3 Neuropsychiatric and behavioural symptoms in Alzheimer’s disease .......... 5 
1.1.4 Primary Psychosis vs. Secondary Psychosis .................................................. 6 
1.2 Psychosis and Alzheimer’s disease .......................................................................... 6 
1.2.1 Delusions in Alzheimer’s disease: Cognitive models and neuroanatomical 
correlates ..................................................................................................... 7 
1.2.2 Hallucinations in Alzheimer’s disease: Cognitive models and 
neuroanatomical correlates ....................................................................... 10 
1.3 Genetic Correlates of Psychosis ............................................................................. 11 
1.3.1 Cholinergic System ...................................................................................... 12 
1.3.2 Dopaminergic System .................................................................................. 12 
1.3.3 Glutamatergic System .................................................................................. 13 
1.3.4 Current Treatment Approaches .................................................................... 13 





1.5 Rationale and Hypothesis ....................................................................................... 15 
Chapter 2 ........................................................................................................................... 16 
2 Methods ........................................................................................................................ 16 
2.1 ADNI Overview .................................................................................................... 17 
2.2 Participants ............................................................................................................ 17 
2.3 Demographic and Behavioural Data Analysis ...................................................... 18 
2.4 Neuroimaging Data Preprocessing and FreeSurfer Analysis ................................ 19 
2.5 Genetic Data Acquisition and Preprocessing ........................................................ 20 
2.6 Candidate SNP Selection ...................................................................................... 21 
2.7 Statistical Analysis ................................................................................................ 26 
2.7.1 Partial Least Squares Correspondence Analysis: Overview ........................ 26 
2.7.2 PLS-CA ........................................................................................................ 27 
2.7.3 Principal Component Analysis and Binary Logistic Regression ................. 28 
Chapter 3 ........................................................................................................................... 30 
3 Results .......................................................................................................................... 30 
3.1 Imaging and Genetics: PLS-CA Results ............................................................... 31 
3.1.1 Delusion Cohort ........................................................................................ 31 
3.1.2 Hallucination Cohort ................................................................................. 36 
3.1.3 Combined Cohort ...................................................................................... 40 
3.2 Neuroimaging Only Analysis ............................................................................... 45 
3.2.1 Delusion Cohort ........................................................................................... 45 
3.2.1 Hallucination Cohort .................................................................................... 51 
Chapter 4 ........................................................................................................................... 57 
4 Discussion .................................................................................................................... 57 
4.1 Discussion Overview ............................................................................................ 58 





4.3 Hallucinations in Alzheimer’s Disease ................................................................. 60 
4.4 The Co-occurrence of Delusions and Hallucinations in Alzheimer’s Disease ..... 63 
4.5 Limitations and Future Directions ........................................................................ 64 
5 Conclusions .................................................................................................................. 66 
Appendix ........................................................................................................................... 67 
References ......................................................................................................................... 69 





List of Tables  
Table 1. Candidate single nucleotide polymorphisms (SNPs) in the Cholinergic (BCHE, 
CHRNA7) and the Dopaminergic (COMT, DRD1, DRD2, DRD3) neurotransmitter systems.
................................................................................................................................................. 23 
Table 2. Candidate single nucleotide polymorphisms (SNPs) in the Glutamatergic (GRIN2A, 
GRIN2B, GRIN3A, GRIN3B) neurotransmitter system. ....................................................... 25 
Table 3. PLS-CA Delusion Cohort: Demographic and disease profile. ................................. 32 
Table 4. PLS-CA - Delusion Cohort. Minor allele frequencies for the 15 SNPs of interest .. 33 
Table 5. Delusion Cohort: Neuroimaging boot-strap regression, summary of ROIs with 
cortical thickness values below the grand mean for Component 1. ........................................ 35 
Table 6. PLS-CA Hallucination Cohort: Demographic and disease profile ........................... 37 
Table 7. PLS-CA - Hallucination Cohort. Minor allele frequencies for the 15 SNPs of 
interest. .................................................................................................................................... 37 
Table 8. Hallucination Cohort: Neuroimaging boot-strap regression, summary of significant 
ROIs with cortical thickness values below the grand mean for Component 1. ...................... 39 
Table 9. PLS-CA Combined Cohort: Demographic and disease profile ................................ 41 
Table 10. PLS-CA - Combined Cohort. Minor allele frequencies for the 15 SNPs of interest
................................................................................................................................................. 42 
Table 11. Combined Cohort: Neuroimaging boot-strap regression, summary of significant 
ROIs with cortical thickness values below the grand mean for Component 1. ...................... 44 
Table 12. Imaging only analysis: Delusion cohort demographic and disease profile ............ 47 
Table 13. Delusion Cohort: Rotated component matrix. Colours indicate ROIs loading most 
strongly to each component based on component scores. Loadings below 0.3 have been 





Table 14. Imaging only analysis: Hallucination cohort demographic and disease profile ..... 53 
Table 15. Hallucination Cohort: Rotated component matrix. Colours indicate ROIs loading 
most strongly to each component based on component scores. Loadings below 0.3 have been 






List of Figures  
Figure 1. Delusion Cohort PLS-CA results. A. Component p-values and latent variable (LV) 
plot for Component 1. The horizontal axis represents the SNPs and the vertical axis 
represents the brain regions of interest. Ellipsoids indicate boot-strap confidence intervals 
(95%) B. Neuroimaging boot-strap regression results for Component 1 with blue bars 
indicating significant brain regions. Red dashed line indicates the threshold for significance 
(+2 and -2) C. Single nucleotide polymorphisms boot-strap regression results for Component 
1 with blue bars indicating significant SNPs. ......................................................................... 34 
Figure 2. Hallucination Cohort PLS-CA results. A. Component p-values and latent variable 
(LV) plot for Component 1. The horizontal axis represents the SNPs and the vertical axis 
represents the brain regions of interest. Ellipsoids indicate boot-strap confidence intervals 
(95%) B. Neuroimaging boot-strap regression results for Component 1 with blue bars 
indicating significant cortical regions and red bars indicating significant subcortical regions. 
Red dashed line indicates the threshold for significance (+2 and -2) C. Single nucleotide 
polymorphisms boot-strap regression results for Component 1 with blue bars indicating 
significant SNPs. ..................................................................................................................... 38 
Figure 3. Combined Cohort PLS-CA results. A. Component p-values and latent variable 
(LV) plot for Component 1. The horizontal axis represents the SNPs and the vertical axis 
represents the brain regions of interest. Ellipsoids indicate boot-strap confidence intervals 
(95%) B. Neuroimaging boot-strap regression results for Component 1 with blue bars 
indicating significant brain regions. Red dashed line indicates the threshold for significance 
(+2 and -2) C. Single nucleotide polymorphisms boot-strap regression results for Component 






   List of Abbreviations  
 
AD Alzheimer's disease 
SCD Subjective cognitive decline 
MCI Mild cognitive impairment 
MoCA Montreal cognitive assessment 
aMCI Amnestic mild cognitive impairment 
naMCI Non-amnestic mild cognitive impairment 
EOAD Early-onset Alzheimer's disease 
LOAD Late-onset Alzheimer's disease 
APOE Apolipoprotein E 
NFTs Neurofibrillary tangles 
NPS Neuropsychiatric symptoms 
BPSD Behavioural and psychological symptoms of dementia 
NPI Neuropsychiatric inventory 
NPI-Q Neuropsychiatric inventory questionnaire 
AD+P Alzheimer's disease with psychotic symptoms 
SPECT Single photon emission computed tomography 
PET Positron emission tomography 
AD+D AD with delusions 
LBD Lewy body dementia 






GWAS Genome-wide analysis studies 
SNP Single nucleotide polymorphisms 
COMT Catechol-O- methyltransferase  
ADNI Alzheimer's Disease Neuroimaging Initiative 
MRI Magnetic Resonance Imaging 
CDR Clinical dementia rating scale 
MMSE Mini-mental state exam 
TIV Total intracranial volume 
QC Quality control 
IBD Identity by descent 
MAF Minor allele frequency 
CEU Utah residents with ancestry from northern and western Europe 
YRI Yoruba in Ibadan, Nigeria 
JPT Japanese in Tokyo, Japan 
TSI Tuscans in Italy 
CHB Han Chinese in Beijing, China 
MDS Multidimensional scaling 
BCHE Butyrylcholinesterase 
CHRNA7 Cholinergic Receptor, Nicotinic Alpha 7 Subunit 
DRD1 Dopamine Receptor D1 
DRD2 Dopamine Receptor D2 
DRD3 Dopamine Receptor D3 
NMDA N-methyl-D-aspartate 





GRIN2B Glutamate Ionotropic Receptor NMDA Type Subunit 2B 
GRIN3A Glutamate Ionotropic Receptor NMDA Type Subunit 3A 
GRIN3B Glutamate Ionotropic Receptor NMDA Type Subunit 3B 
PLS-CA Partial least squares correspondence analysis 
ROI Region of interest 
AD-DH AD without symptoms of delusions or hallucinations 
AD AD with both symptoms of delusions and hallucinations 
PCA Principal component analysis 









Chapter 1  




















1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and is the most 
common cause of dementia. It affects close to 560,000 individuals in Canada alone and 
around 44 million people worldwide with the prevalence projected to double in the next 
ten years 1,2. Importantly, the cognitive and functional deficits that arise from AD are 
more advanced than typical age-related cognitive decline and may present many years 
prior to an established clinical diagnosis of AD. With a growing aging population in 
Canada and worldwide, AD is not only a pressing concern for individuals and care-givers, 
but also represents a much larger public health issue. As such, research endeavors aiming 
to identify and characterize the underlying biological substrates contributing to the 
progression of AD and its associated symptoms are increasingly important as a starting 
avenue for the development of therapeutic interventions. 
1.1.1 Stages of Cognitive Impairment and Progression to Alzheimer’s 
Disease 
AD is associated with gradual cognitive decline, with the specific disease trajectory for 
each individual being modulated by a combination of biological, social and psychological 
factors. Initial indications of prodromal AD are often reported as subjective cognitive 
decline (SCD) with patients endorsing symptoms of worsening cognitive function without 
clear impairments on cognitive screening tests 3,4. As cognitive functions decline, patients 
may progress to develop Mild Cognitive Impairment (MCI) – characterized by a mild-
moderate degree of cognitive impairment with preserved activities of daily living. A 
diagnosis of MCI is established through a comprehensive patient history and validated 
cut-off scores on neuropsychological testing including the Mini Mental State Exam 
(MMSE) 5 and the Montreal Cognitive Assessment (MoCA)6,7. An important distinction 
to note, is that those with MCI can be categorized into two major subgroups – amnestic 
MCI (aMCI) and non-amnestic MCI (naMCI), with the key distinguishing feature 
between the latter and the former being the predominance of memory impairments 8. 
aMCI is often referred to as MCI due to AD, given its increased risk of progression to 
AD, with one study identifying an 8.5-fold increased risk for those with probable aMCI of 
converting to dementia 9. This distinction has been further supported by structural 
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neuroimaging studies which implicate a greater reduction in volume and cortical 
thickness of key memory structures such as the hippocampus and the entorhinal cortex in 
patients with aMCI when compared to naMCI and healthy older controls 10. Eventual 
progression to AD is characterized by severe cognitive and functional impairments that 
limit one’s ability to carry out activities of daily living. These symptoms include memory 
loss, impaired reasoning and judgement, and changes in personality and behaviour – 
likely attributable to advanced neurodegeneration that hinders the brain’s ability to 
compensate for disruptions in regional cortical networks.  
Early-Onset Alzheimer’s Disease (EOAD). About 5.5% of individuals diagnosed with 
AD are affected by early-onset or familial AD 11. EOAD differs from late-onset 
Alzheimer’s disease (LOAD) in that it affects individuals who are less than 65 years of 
age. Individuals with EOAD with a family history of AD may present with genetic 
mutations linked to three key genes – the Amyloid Precursor Protein 12, Presenilin 113, 
and Presenilin 2 14. Mutations in these genes have been found to be associated with the 
accumulation of beta-amyloid in the brain contributing to increased plaque pathology.  
Late-Onset Alzheimer’s Disease (LOAD). LOAD is a term used to classify individuals 
who develop AD after the age of 65. The greatest risk factor for LOAD is age, with the 
risk of AD doubling every 5 years after the age of 60 15. In addition to age, other genetic 
and environmental factors may also contribute to the development of LOAD. The major 
genetic risk factor for LOAD is the apolipoprotein E (APOE) gene, a key gene in the 
central and peripheral nervous system involved in lipid transport 16,17. In particular, when 
compared to the more common E3/E3 genotype, those with one copy of the E4 allele 
have a three-fold increased risk of AD, while those with two copies of the allele have an 
8-12 fold increased risk 18,19. The mechanism by which the E4 allele is thought to 
contribute to AD pathology is through the decreased ability to clear beta-amyloid, leading 
to the aggregation of beta-amyloid into fibrils and plaques which subsequently contribute 
to disruptions in synaptic connectivity and neurodegeneration in AD 20.The 
immunoreactivity of ApoE has also been shown to be associated with amyloid deposits 
and neurofibrillary tangles 21. Protective factors against AD include carrying the E2 allele 
of the APOE gene, more years of formal education, physical activity, and social 
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engagement 22–25. Both increased educational attainment and social activity are thought to 
be protective against AD due to their proposed ability to increase cognitive reserve. In 
this case, cognitive reserve refers to the brain’s ability to adapt to pathological changes 
arising from AD, by using either compensatory strategies or other means of cognitive 
appraisals. Overall, these observations suggest that increased cognitive reserve may make 
individuals more resilient to early disruptions in normal cognitive functioning arising 
from the pathology of AD, and delay the onset of identifiable cognitive impairment 26–28.  
1.1.2 Neuropathology of Alzheimer’s disease. 
The two cardinal pathological features of Alzheimer’s disease – beta-amyloid plaques and 
neurofibrillary tau tangles (NFTs), were first identified and described by Alois 
Alzheimer29,30. The aggregation of extracellular beta-amyloid, in particular the neurotoxic 
Aß42 form of the protein, has been identified to lead to the formation of oligomers and 
senile plaques throughout the brain in patients with AD 31,32. Beta-amyloid has also been 
implicated in the amyloid cascade hypothesis which postulates that AD progression is 
driven by the accumulation of insoluble extracellular beta-amyloid plaques. This 
accumulation is thought to disrupt downstream processes and contribute to the abnormal 
phosphorylation of tau proteins. Collectively, both the beta-amyloid and tau pathology 
arising from this cascade is thought to lead to disruptions in synaptic connectivity and 
ultimately neuronal death 33.  
NFTs are abnormally phosphorylated tau proteins localized within neurons. The 
accumulation of phosphorylated tau proteins leads to misfolding and disruption of 
intraneuronal cytoskeletal architecture resulting in decreased cell stability 34–36. NFTs are 
initially found regionally distributed in cortical and subcortical structures involved in 
memory and cognitive function, with their presence in these regions corresponding with 
early symptoms characteristic of AD. These include structures within the temporal lobe 
such as the entorhinal cortex, hippocampus, amygdala and posterior parahippocampal 
regions 37. Overtime, paralleling disease progression, NFTs become more dispersed and 
affect structures involved in language, personality and motor coordination. Given the 
positive correlation between NFT pathology and AD progression, clinical evaluations 
characterize AD progression using NFT pathology as a severity and stage marker of AD 
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38. Taken together, both beta-amyloid plaques and NFTs are associated with disruptions in 
normal cell-signaling which ultimately manifests biologically as localized cortical 
atrophy in regions affected by these lesions, and behaviorally as impairments in memory, 
language and other cognitive and non-cognitive domains.  
1.1.3 Neuropsychiatric and behavioural symptoms in Alzheimer’s 
disease  
In addition to cognitive impairments, many patients with AD also develop non-cognitive 
symptoms such as neuropsychiatric symptoms which are interchangeably referred to as 
behavioural and psychological symptoms of dementia. The prevalence of these symptoms 
in patients with dementia has been shown to be nearly universal with close to 97% of 
patients developing at least one neuropsychiatric symptom 39. The comorbid presentation 
of AD with neuropsychiatric symptoms has been shown to be associated with more rapid 
cognitive decline, higher rates of institutionalization, and greater care-giver and financial 
burden 40–42. In a clinical setting, the most widely used assessment for  neuropsychiatric 
symptoms in individuals with dementia is the Neuropsychiatric Inventory (NPI)43. The 
NPI evaluates the frequency and severity of 12 neuropsychiatric symptoms including 
delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, 
disinhibition, aberrant motor behaviour, night-time behaviour disturbances, and appetitive 
and eating abnormalities. The NPI has also been adapted into a validated brief clinical 
form known as the Neuropsychiatric Inventory Questionnaire (NPI-Q)44 which assesses 
the presence or absence of these neuropsychiatric symptoms. A systematic review by 
Zhao and colleagues (2016) found that in patients with AD, apathy was the most common 
NPS with a prevalence of 49%, while euphoria was the least common with a prevalence 
of 7%. Further studies have used techniques such as factor analysis to categorize these 
symptoms into distinct subgroups including, 1) Hyperactivity (agitation, disinhibition, 
irritability, and aberrant motor behaviours); 2) Psychosis (hallucinations, delusions, night-
time behaviour disturbance); 3) Affective (depression, anxiety); and 4) Apathy 45. Of 
particular importance is that the psychosis subsyndrome was associated with the highest 
overall NPI score, suggesting that the presence of these symptoms may further exacerbate 
cognitive and functional decline in patients with AD. 
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1.1.4 Primary Psychosis vs. Secondary Psychosis  
Psychotic symptoms are common and characteristic phenomenon of primary psychotic 
disorders such as schizophrenia but may also arise as presenting symptoms in other 
diseases 46. When psychosis arises as a symptom of a pre-existing medical condition, for 
example as a symptom of delirium 47, neurologic, or neurodegenerative disorder, this 
presentation is referred to as secondary psychosis. A key distinguishing feature of 
primary psychosis from secondary psychosis arising from AD, is that on cognitive 
screening, those with primary psychosis retain the ability to remain oriented to the world 
around them 48. When comparing the two most common psychotic symptoms – delusions 
and hallucinations, in those with schizophrenia and AD, a few key differences are 
important to note. Firstly, delusional symptoms in schizophrenia tend to be more complex 
and bizarre, while in AD delusions tend to be simpler, with the most common being 
paranoid delusions such as delusions of theft or infidelity 49,50. This distinction is 
supported by neuroimaging studies which further suggest that delusions in AD may arise 
as a result of progressive memory and cognitive impairments 51,52, which in turn may 
generate states of confusion or paranoia ultimately leading to delusional symptoms 53. 
Secondly, individuals with schizophrenia also predominantly experience auditory 
hallucinations but may also experience hallucinations in other sensory modalities. The 
hallucinations experienced by those with schizophrenia are typically described as 
Schneider’s first-rank symptoms indicating a loss of self vs. non-self distinction (e.g. 
hearing third-person voices talking to one another about oneself, intrusive second-person 
voices commenting on an individual’s thoughts and behaviours)54. In contrast, visual 
hallucinations tend to be more common in  individuals with AD and include seeing 
people or animals 55. While the presentation of psychotic symptoms may vary in those 
with schizophrenia and AD, neuroimaging studies have implicated similar brain regions 
suggesting an overlapping neuropathology, discussed in further detail below, which may 
contribute to the development of hallucinations and delusions in these disorders. 
1.2 Psychosis and Alzheimer’s disease 
The co-occurrence of psychotic symptoms and AD is a devastating phenotype (AD+P) 
that affects close to 40% of individuals with AD 41, making it one of the most common 
7 
 
psychotic disorders  – second only to schizophrenia 49,56. When describing psychotic 
symptoms in AD, the two most common symptoms that fall under this category are 
delusions and hallucinations. Delusions are defined as persistent false beliefs that are 
resistant to reasoning and are independent of any cultural beliefs. Hallucinations are 
defined as sensory perceptions, of any sensory modality, that occur in the absence of any 
external stimuli. Notably, in AD, the presence of these symptoms begins early in the 
disease course and remains persistent over time. For example, a study by Paulsen and 
colleagues (2000)57, showed that in a sample of 329 AD patients, 20% had symptoms of 
hallucinations or delusions at baseline, with the cumulative incidence increasing to 
around 51% at four years follow-up. When compared to other neuropsychiatric symptoms 
in AD, such as agitation, aggression or disinhibition, the grouping of hallucinations and 
delusions into one overarching category in many factor analytic and latent class analysis 
studies, suggests that these symptoms may have some shared neural correlates 45,58,59. But 
when broken down further, more recent studies suggest a divergence in psychotic 
symptomatology and consequently raise the question of whether the final pathway that 
leads to the presentation of hallucinations and delusions in AD may differ 60,61. Studies 
that have subdivided psychotic symptoms to identify the individual prevalence of 
delusions and hallucinations have consistently found that delusions tend to be more 
common in those with AD when compared to hallucinations 62,63. In a systematic review, 
the prevalence of delusions was found to range from 9 – 59% in individuals with AD, 
with a pooled-prevalence of approximately 31%, while the prevalence of hallucinations 
was found to range from 6 – 41%, with a pooled prevalence of approximately 16% 64. 
Given that delusions and hallucinations may be associated with distinct biological 
correlates, developing a better understanding of how they uniquely arise may provide 
greater insight into more specific and targeted treatment options for each symptom. 
1.2.1 Delusions in Alzheimer’s disease: Cognitive models and 
neuroanatomical correlates 
Investigations into the neuroanatomical and pathological correlates of delusions in AD 
have led to the proposition of three key theories that may explain the etiology of 
delusions in AD 65. The first model is known as the hypofrontality model which 
postulates that delusions in AD arise as a result of disrupted frontal lobe function either 
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due to atrophy to frontal brain regions or hypoperfusion in these areas. Evidence in 
support of this model include neuroimaging studies using single photon emission 
computed tomography (SPECT) and positron emission tomography (PET) which suggest 
that individuals with AD and delusions (AD+D), when compared to controls, have 
hypoperfusion in frontal brain regions 66–68. A limitation of this theory is that it 
presupposes that all delusional symptoms may arise as a result of frontal pathology 
without acknowledging that different types of delusions for example, misidentification 
and paranoid delusions may have additional unique neural substrates. For example, an 
earlier PET study of AD patients with misidentification delusions, found that patients 
with these delusions compared to AD controls, had more pronounced bilateral cingulate 
and basal ganglia hypometabolism, in particular in regions of the orbitofrontal, middle 
temporal, anterior and posterior cingulate, left caudate nucleus, left lentiform nucleus, and 
the left calcarine69. Results of this study suggest that it may not just be the frontal lobes 
that are implicated in AD+D, but rather coordinated networks of regions which may 
contribute to the presence of specific types of delusions in AD. In particular, given the 
involvement of the basal ganglia, there may be limbic loops extending from subcortical 
structures to frontal regions of the cortex which may explain the distressing emotional 
aspects of delusional symptoms. 
The second theory proposes that delusions may be non-cognitive manifestations of AD 
and are based on research findings that suggest that individuals with AD+D may have 
greater behavioural impairments independent of AD neuropathology when compared to 
those without delusions 70,71. More specifically, this theory proposes that individuals with 
AD+D do not significantly differ in cognitive abilities on neuropsychological testing 
when compared to individuals without delusions, but that they do have more severe 
behavioural symptoms such as aggression and other activity disturbances. As such, 
according to this theory, scores on neuropsychological testing alone would not be 
predictive of the subsequent development of delusions in AD. From a neuropathological 
level, Sweet and colleagues (2000)71 found that AD+P was not associated with increased 
severity of plaque and tangle formation when the sample was controlled for the presence 
of Lewy bodies. A few limitations of this theory include the lack of consideration that 
perhaps aggressive behaviours may make individuals more prone to psychosis or vice 
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versa. Namely, those with symptoms of aggression may be more inclined to exhibit 
paranoid delusions in which they believe that others are stealing from them or fear 
persecution from those around them. Contrarily, delusional belief that others are out to 
get them, may actually perpetuate aggressive behaviours. As such, it would be important 
to dissociate whether delusions exhibited by those with other behavioural symptoms are 
in fact organic delusions or whether they occur in response to, or a result of, aggressive 
behaviours and can be resolved upon treatment of aggressive symptoms. 
In contrast, the third theory proposes that AD+D may arise as a result of the 
pathophysiology of AD. With respect to this theory, the pathophysiology of AD is 
defined in reference to the characteristic features of AD – namely amyloid plaques and 
neurofibrillary tangles. Unlike the aforementioned theory, this model proposes that the 
increased severity of these plaques and tangles may contribute to the presence of 
delusions in AD. In support of this model, studies have found independent associations of 
psychotic symptoms with neurofibrillary tangle density 72 and senile plaques 73. These 
differences in findings when compared to the previously described theory could be 
attributed to the lack of control for those with Lewy body dementia (LBD), as well as 
different methodological approaches with regards to specific brain regions that were 
investigated.  
While these theories have been used to describe the biological correlates of delusions 
more generally, it is important to note that delusions in AD can be categorized into two 
major subgroups – paranoid and misidentification delusions 74. Paranoid delusions 
include delusions of persecution, theft, as well as infidelity. Misidentification delusions 
include Capgras syndrome in which an individual believes someone close to them has 
been replaced by an imposter; TV sign, in which they believe that characters or situations 
depicted on TV shows are real; and phantom boarder syndrome in which they believe that 
a stranger is inhabiting their house. In contrast to the theories proposed above, a review of 
more recent studies suggest that paranoid and misidentification delusions may have 
distinct neuropathological correlates, with paranoid delusions being associated with more 




In addition to these three theories, many studies also suggest a hemispheric lateralization 
for delusions, with the majority of studies implicating right hemisphere dysfunction 
57,67,76. In particular, it has been hypothesized that atrophy in the right hemisphere may 
lead to changes in memory, thinking, reality monitoring failure, and impairments in 
autobiographical memory retrieval, which in turn may manifest as delusional judgements 
or beliefs that can be communicated if there is relative preservation of the left hemisphere 
77,78.  Collectively, these theories suggest that there may be multiple factors contributing 
to the pathology of AD+D, with the majority suggesting involvement of the frontal lobes 
as being the driving factor behind delusional beliefs.  
1.2.2 Hallucinations in Alzheimer’s disease: Cognitive models and 
neuroanatomical correlates 
Hallucinations in Alzheimer’s disease (AD+H) can be associated with any sensory 
modality but the two most common types of hallucinations in AD tend to be visual and 
auditory 79–81. Understanding the underlying biological correlates of hallucinatory 
symptoms is increasingly important since previous research suggests that the presence of 
hallucinations in AD is associated with more rapid cognitive deterioration and an 
increased risk of mortality 82–84. With regards to the neuroanatomical correlates of 
hallucinations, some studies suggest the involvement of corresponding sensory brain 
regions with particular modalities of hallucinations (i.e. primary auditory cortex in 
auditory hallucinations, visual cortex for visual hallucinations) and go further to suggest 
that specific brain regions may be linked to the content of hallucinations 85. Being able to 
correlate hallucinations with specific brain regions is particularly important because it 
may suggest that localized pathological abnormalities are associated with subtypes of 
hallucinations and therefore help to guide more targeted treatment options. 
When looking at the neuroanatomical correlates of hallucinations in AD specifically, 
there have been conflicting hypotheses as to what may generate these symptoms. Some 
studies suggest that visual hallucinations may arise as a result of occipital lobe atrophy 86, 
while others suggest that relative preservation of the cortex is necessary to generate 
psychotic symptoms in AD 87. In support of the posterior atrophy and hypometabolism 
model, one study found that subcortical white matter lesions in occipital regions – 
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hypothesized to be an indication of abnormalities in the primary visual pathway, were 
associated with AD+H in the absence of any visual acuity deficits 88. Controlling for 
visual acuity is particularly important in an elderly population, given that other neurologic 
deficits, such as Charles Bonnet syndrome may also give rise to hallucinations 89. Charles 
Bonnet syndrome is also characterized by symptoms of visual hallucinations but in this 
case these symptoms arise as a result of vision loss from eye conditions such as macular 
degeneration. In addition to the neuroanatomical correlates of hallucinations, one study 
also suggests that hallucinations in AD are associated with a decline in inhibitory control 
and difficulty in suppressing intrusive memories or thoughts which may then be 
misattributed to external stimuli 90. Overall, given the heterogeneity of hallucinations, 
there is no clear consensus in the field as to what may be the underlying mechanism of 
hallucinations in AD, but the existing literature does suggest that brain regions involved 
in different sensory process may be associated with hallucinations of the same modality. 
1.3 Genetic Correlates of Psychosis   
While there is significant evidence that regional brain atrophy may contribute to the 
formation of hallucinations and delusions, what remains unclear is why a proportion of 
individuals with AD develop psychotic symptoms while others remain asymptomatic 
throughout their disease course. To address this variability, some studies have looked into 
the heritability of AD+P and have found evidence of a familial aggregation of AD+P 
60,91,92. These studies have also identified a heritable component, with one study 
estimating the heritability of LOAD and psychotic symptoms to be around 61% 93. 
Collectively, these studies provide strong evidence in support of a genetic component to 
AD+P and highlight the importance of understanding the genetic factors which may 
contribute to the development of psychotic symptoms in AD. Genetic variants in 
neurotransmitter pathways are of particular interest, given the modulation of psychotic 
symptoms by treatments that target neurotransmitters in several neuropsychiatric 
disorders. More specifically, studies that have examined neurotransmitters involved in the 
development of schizophrenia as well as other neurodegenerative diseases that present 
with psychiatric symptoms, such as AD, have implicated a role of the cholinergic, 
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dopaminergic and glutamatergic neurotransmitter system in the development of delusions 
and hallucinations.  
1.3.1 Cholinergic System 
One of the pathologies of Alzheimer’s disease is the loss of neurons in the Nucleus 
Basalis of Meynert, a major source of cholinergic innervation to the cerebral 
cortex94,95.The neurotransmitter acetylcholine (ACh) plays an important role in memory, 
arousal and learning. Consequently, the cholinergic deficiencies which arise in AD have 
led to the development of the cholinergic hypothesis in explaining the cognitive and 
behavioural changes, including neuropsychiatric symptoms, in AD 96,97. The cholinergic 
hypothesis of neuropsychiatric symptoms in AD proposes that the projections from the 
nucleus basalis, which enables limbic-neocortical interactions, becomes disrupted and 
consequently alters emotional and motivational states, leading to the observed 
behavioural changes in AD 98. Recent genome-wide analysis studies (GWAS) have begun 
to investigate single nucleotide polymorphisms (SNPs) in neurotransmitter systems to 
identify if certain polymorphisms may be risk factors for the development of psychosis in 
AD 99. For example, a significant association between the development of delusions and a 
polymorphism (rs6494223) in the alpha-7 nicotinic acetylcholine receptor gene has been 
identified 100. Moreover, patients treated with donepezil, a cholinesterase inhibitor, have 
shown improvements in delusional symptoms suggesting that imbalances in the 
cholinergic system, in particular within frontal brain regions, may be associated with the 
emergence of delusional symptoms in AD101. 
1.3.2 Dopaminergic System 
The dopamine system has been extensively studied in relation to the positive and negative 
symptoms of schizophrenia. More specially, the dopaminergic hypothesis postulates that 
the positive symptoms of schizophrenia (i.e. hallucinations, delusions etc.) may arise as a 
result of increased dopamine levels in the striatum, stemming from increased D2/D3 
receptor density 102,103. Given the findings that symptoms of psychosis may arise as a 
result of dopamine irregularities, studies have likewise examined the effect of dopamine 
specific polymorphisms and the development of psychotic symptoms in 
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neurodegenerative diseases. One such study by Sweet and colleagues (1998)104, found 
that polymorphisms in the dopamine D1 and D3 receptor conferred a moderate risk of 
developing psychotic symptoms in AD. Similarly, a polymorphism in the catechol-O- 
methyltransferase (COMT) gene, which leads to the upregulation of striatal dopamine, 
has been shown to be a risk factor for the development of psychosis in AD 105. 
1.3.3 Glutamatergic System 
The glutamate system is likewise an appropriate candidate system to assess in relation 
with psychotic symptoms given that abnormal glutamate activity in schizophrenia is 
hypothesized to contribute to the development of hallucinations and delusions. Studies 
such as those conducted by Mogahaddam et al., (1997)106 and Bickel and Javitt (2009)107, 
provide support that antagonism of NMDA receptors elevates extracellular glutamate 
levels which may in turn lead to the development of psychotic symptoms similar to those 
seen in schizophrenia. On the other hand, excessive NMDA activity is associated with 
neurotoxicity which can lead to neuronal cell death, as can been seen in many 
neurodegenerative diseases such as AD 108. To further support the role of the glutamate 
system in the development of psychotic symptoms, Begni and colleagues (2003)109, found 
that the G1001C polymorphism in the Glutamate Ionotropic Receptor NMDA Type 
Subunit 1, in particular the C allele, was significantly associated with an increased risk of 
Schizophrenia (OR = 2.04). Through examining the functional effects of the G1001C 
polymorphism, the authors identified that this polymorphism may exert its biological 
effects by altering the consensus sequence in the nuclear factor kappa-light-chain 
enhancer of activated B-cells (NF-kB) transcription factor, a protein complex involved in 
DNA transcription. As such, investigating polymorphisms in the glutamate system may 
provide additional information on how psychotic symptoms may arise in AD. 
1.3.4 Current Treatment Approaches 
Current treatment approaches for psychotic symptoms in AD include the use of atypical 
antipsychotics such as risperidone, olanzapine, and aripiprazole but have been associated 
with limited efficacy and severe side effects in patients with dementia, deriving from a 
lack of biological specificity. A review of 16 placebo-controlled trials suggests that the 
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use of risperidone may modestly improve psychotic symptoms in AD but is also 
associated with severe adverse outcomes including cerebrovascular and extrapyramidal 
side effects. Given the modest efficacy and vast side-effect profile, it was concluded that 
risperidone should not be used to routinely treat patients with AD+P 110. A subsequent 
review identified that those with more severe symptoms of AD+P were those that may 
benefit the most from risperidone treatment 111. Aside from risperidone, a clinical trial of 
aripiprazole in patients with a definitive diagnosis of AD+P, showed only a modest 
benefit when compared to placebo in improving psychotic symptoms. One identified 
benefit of aripiprazole when compared to other atypical antipsychotics, was that it was  
associated with minimal adverse side effects in patients with AD, although it did have 
minor negative effects on cognition 112. However, it is also important to note that a review 
looking at the mortality rates associated with general atypical antipsychotic use found that 
there was an increased risk of mortality in patients with dementia that used these drugs 
(OR: 1.54)113. These findings of adverse and limited side-effects associated with current 
treatments for psychosis in AD, reiterate the importance of identifying more specific 
treatment options that target psychotic symptoms in AD. This is particularly important 
given that earlier interventions may improve the quality of life of those with AD+P, 
reduce long-term health care costs, and reduce the risk of institutionalization.  
1.4 Neuroimaging and Genomics 
Previous research has examined whether regional brain changes or genetic 
polymorphisms in neurotransmitter systems may give rise to psychotic symptoms. 
However, the results to date have been inconsistent because of a lack of dissociation of 
psychosis into the different subtypes. In addition, few studies have linked brain imaging 
and genetics together to investigate how the interaction between these two factors may 
mediate the presence of hallucinations and delusions in AD specifically. A previous study 
using neuroimaging genomics (the integration of neuroimaging and genetic techniques) 
and machine learning to predict AD, showed that adding genetics (in particular SNPs) to 
other imaging modalities may help improve the classification accuracy of AD 114. One 
other study used large scale brain mapping for gene discovery to look specifically for 
SNPs that may be associated with temporal lobe volume. This study found that the risk 
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allele for rs10845840 located in the GRIN2B gene was associated with lower temporal 
lobe volume and overrepresented in AD/MCI subjects when compared to controls 115. 
Although these studies did not look at particular symptoms of AD, these findings suggest 
that considering the interaction between neuroimaging and genetic factors may provide 
additional valuable information to aid in classification of participants. This is particularly 
important for psychotic symptoms in AD, given that hallucinations and delusions may 
arise as a result of imbalances in different neurotransmitter systems which may become 
more pronounced as a result of regional brain changes arising from AD.  
1.5 Rationale and Hypothesis  
The purpose of this study was to investigate the relationship between regional brain 
changes and genetic polymorphisms in neurotransmitter systems and the presence of 
hallucinations and delusions in AD. Given prior findings that there may be anatomical 
variations in individuals with AD, we sought to investigate whether these differences may 
indicate different phenotypes of AD. In particular, with regards to psychotic symptoms in 
AD, studies suggest that the frequency of these symptoms may vary across individuals 
with AD, with some individuals developing psychosis and others remaining 
asymptomatic throughout their disease course. Furthermore, there remains limited 
evidence and consensus in the literature with regards to particular brain regions that may 
be associated with symptoms of hallucinations and delusions. As such, we hypothesized 
that the interactions between regional brain structures and genetic variants in cholinergic, 
dopaminergic or glutamatergic neurotransmitter systems would be associated with 
symptoms of psychosis in AD, and that the distinct nature of these interactions would 
differ for those with delusions when compared to those with hallucinations. More 
specifically, we rationalized that investigating the interactions between regional brain 
changes and genetic variants would be critical in identifying whether the functional 
effects of specific genetic polymorphisms are unmasked as a result of regional brain 
changes arising from AD. We predicted that delusions and hallucinations are 
predominantly caused by the interaction of right frontal brain changes and genetic 


























2.1 ADNI Overview 
Data used in the preparation of this article was obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 
2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, 
MD. The primary goal of ADNI has been to test whether serial magnetic resonance 
imaging (MRI), positron emission tomography (PET), other biological markers, and 
clinical and neuropsychological assessments can be combined to measure the progression 
of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). All subjects in 
ADNI undergo both cognitive and clinical assessments and have structural MRIs taken 
for 2-3 years at pre-scheduled intervals. AD patients undergo a baseline assessment and 
then an assessment at, 6, 12 and 24 months. MCI patients at high risk for conversion to 
AD undergo a baseline assessment and then subsequent assessments at 6, 12, 18, 24 and 
36 months. Participants from earlier ADNI cohorts were also followed in ADNI2/GO and 
ADNI3 where they were assessed at baseline enrollment, month 3, month 6, month 12, 
and annually thereafter. For up-to-date information, see www.adni-info.org.   
2.2 Participants 
Subjects were selected from the ADNI database and categorized into distinct subgroups 
based on endorsed symptoms of psychosis as assessed by the Neuropsychiatric Inventory 
(NPI)43 or Neuropsychiatric Inventory questionnaire (NPI-Q)44. Inclusion criteria for 
patients endorsing psychotic symptoms included a clinical diagnosis of AD or MCI due to 
AD, at least one episode of delusions or hallucinations as assessed by either the NPI or 
NPI-Q delusion and/or hallucination domain scores, an available UCSF volumetric 
measurement of a 1.5T or 3T MRI scan at or after the first onset of psychosis 
(delusions/hallucinations), and genome wide analysis data. Inclusion criteria for control 
participants included a clinical diagnosis of AD, the absence of delusions and 
hallucinations throughout the course of the ADNI studies, at least three available UCSF 
volumetric measurement of a 1.5T or 3T MRI scan, and available genome wide analysis 
data, as of ADNI data available on January 1, 2018. Exclusion criteria for both groups 
included a history of brain injury, other neurological disorders (ex. Dementia with Lewy 
Bodies, Parkinson’s disease etc.), psychiatric disorders (ex. Schizophrenia, Bipolar 
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disorder etc.) or strokes, as determined based on clinical assessment, which could account 
for the presence of delusions and/or hallucinations. 
All participants who developed psychotic symptoms were matched as closely as possible 
with AD patients that did not develop that particular symptom (i.e. hallucinations or 
delusions) for disease severity using the scores from the Clinical Dementia Rating scale 
(CDR) global score, sex, age, cognitive ability using the Mini Mental State Exam 
(MMSE) total score, years of education, number of ApoE4 alleles, and MRI scanner 
strength. To match the group of participants endorsing symptoms of psychosis with the 
control group, the range of values of age, education, CDR global score, and MMSE total 
score for those endorsing symptoms of delusions and/or hallucinations were applied as a 
filter to the available control group. 
2.3 Demographic and Behavioural Data Analysis 
Delusion and hallucination domain scores from the Neuropsychiatric Inventory 
Questionnaire (NPI-Q) and the full Neuropsychiatric Inventory (NPI) were extracted from 
the ADNI database for participants meeting the inclusion criteria as defined above on 
January 1, 2018. Phase 1 of ADNI (ADNI-1) used the NPI-Q which provides a binary 
response (yes or no) to assess the presence or absence of symptoms for each domain. 
Phase 2 of ADNI (ADNI-GO/2) used the full NPI which allows for the identification of 
specific subtypes of neuropsychiatric symptoms. Prompts for the delusion domain on the 
NPI include paranoid ideations such as believing that their life is in danger or that others 
are stealing from them, and misidentification phenomenon such as believing that their 
spouse is not who they claim to be. Prompts for the hallucination domain on the NPI 
include endorsement of abnormal visual, auditory, olfactory, or tactile sensations and/or 
perceptions in the absence of any external stimuli; for example, hearing voices or seeing 
things that are not actually present. For participants endorsing psychotic symptoms on 
multiple visits, data from the first ADNI visit in which psychotic symptoms 
(delusions/hallucinations) were present were included in the analysis. For the control 
group, the NPI and NPI-Q scores for all available ADNI visits were reviewed to ensure 




2.4 Neuroimaging Data Preprocessing and FreeSurfer 
Analysis 
High resolution anatomical T1weighted images were preprocessed by the Mayo Clinic. 
Initial preprocessing included a two-step quality assessment procedure. The first step 
involved assessing adherence to defined ADNI MRI collection protocol. The second 
preprocessing step involved series-specific quality assessment and included gradient 
warping, scaling, and correction for image intensity and inhomogenities. Preprocessed 
ADNI cross-sectional data [UCSFFSX] images were then analyzed by the UCSF ADNI 
group (Co-I Norbert Schuff) using FreeSurfer version 4.3 for images collected at 1.5T 
and FreeSurfer version 5.1 for images collected at 3T. Although two different field-
strengths were used, FreeSurfer procedures have been shown to have good re-test 
reliability across field strengths116,117. The T1 weighted images were processed and 
segmented using the 2010 Deskian-Killany atlas and the 2009 Destrieux atlas. Briefly, the 
processing steps included segmentation of grey matter, white matter and subcortical 
structures and subsequent cortical parcellation. A visual quality control was performed to 
assess overall segmentation accuracy118–129. It is important to note that cortical thickness 
estimates have been shown to vary across different versions of FreeSurfer130, but it has 
also been shown that within the ADNI cohorts, FreeSurfer version does not affect the 
reliability of patient classification on diagnostic group (healthy controls, MCI or AD) 
based on cortical thickness measurements obtained from FreeSurfer131. 
In order to conduct a whole brain analysis, eighty-two cortical and subcortical regions of 
interest (ROI) from the UCSF FreeSurfer cross-sectional ADNI data analysis were 
included (Appendix A). Cortical thickness and subcortical volume measurements for the 
ROIs were extracted. To account for individual variations in brain size, all subcortical 
volume measurements were adjusted for total intracranial volume (TIV). This was done 
since prior literature suggests that volume but not cortical thickness measurements are 
highly correlated with TIV 132–134. MRI data was only included if it passed or partially 
passed regional image segmentation quality assessment of the frontal, temporal, occipital 
and basal ganglia regions. For subsequent statistical analyses, volume and cortical 
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thickness measurements were adjusted for sex, age, years of education, CDR global score, 
MMSE total scores, either through regression models or by including these variables as 
covariates. All cortical and subcortical measurements were also transformed into z-scores 
before further analyses. 
2.5 Genetic Data Acquisition and Preprocessing 
DNA information was derived from one of two sources: 1) peripheral blood, or 2) 
immortalized lymphocyte cell lines. ADNI-1 participants were genotyped using the 
Illumina Human610-Quad BeadChip (Illumina, Inc. San Diego, CA). All genotyping and 
initial preprocessing was conducted by the ADNI Genetics Core group. Further details on 
genotyping methods and preprocessing have been outlined by the ADNI Genetics Core 
group 135.  Initial quality control (QC) and imputation was performed by Sejal Patel and 
the lab of Dr. Jo Knight at the University of Toronto. Genotype imputation is a procedure 
whereby unsequenced SNPs are inferred based on directly sequenced SNPs. This 
procedure works on the premise that groups of SNPs are likely to be inherited together 
(haplotypes). SNPs that have been sequenced act as markers which are then compared to 
the haplotypes of individuals in a reference panel (ex. HapMap). Regions of shared 
genotypes between the sequenced individuals and the reference panel are then identified. 
The reference panel is then used to infer unsequenced genotypes for SNPs that were not 
directly sequenced136.  
 
QC was performed on the ADNI1 GWAS data (N=757) using PLINK (version 1.07, 
Purcell et al., 2007). Individuals with discordant sex information (when samples are 
incorrectly marked as male or female based on ascertained sex), high level of missing 
data (> 2%) and heterozygosity rates greater than three standard deviations from the mean 
were removed from the sample. One of each pair of individuals displaying a high level of 
pair-wise identity by descent (IBD > 0.185) were also removed. In addition, SNPs with 
minor allele frequency (MAF) <1% and Hardy-Weinberg equilibrium (p < 1x10-7) were 
removed. After QC, 662 individuals remained in the analysis set. Multidimensional 
scaling (MDS) was performed in PLINK using HapMap3138 as a reference panel. When 
the population was compared with the CEU (CEPH - Utah residents with ancestry from 
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northern and western Europe), YRI (Yoruba in Ibadan, Nigeria), JPT (Japanese in Tokyo, 
Japan), TSI (Tuscans in Italy) and CHB (Han Chinese in Beijing, China) ancestry, the 
sample clustered around CEU and TSI sample. MDS was subsequently carried out with 
the ADNI1, CEU, TSI and Jewish ancestry samples and aligned completely with the later 
three samples. The ADNI1 dataset was imputed using 1000 Genomes Phase I integrated 
variant set (March 2012). Given the small sample size of participants that were of non-
Hispanic Caucasian ethnicity, these individuals were removed prior to subsequent 
analysis to control for any confounding effects. From the preprocessed data, we then 
selected only participants meeting the inclusion criteria defined above.  
2.6 Candidate SNP Selection 
After conducting a thorough review of the literature, we identified SNPs with known 
functional consequences and associations with neuropsychiatric symptoms, focusing in 
particular on SNPs in the following genes in the cholinergic system: BCHE, ACHE, 
CHRNA7, CHRNA4, CHRNB2; and in the following genes in the dopaminergic system: 
COMT, DRD1, DRD2, DRD3; and in the glutamatergic system: GRIN1, GRIN2A, 
GRIN2B, GRIN2C, GRIN2D, GRIN3A. Concluding our review, we selected 15 
candidate SNPs to include (Table 1,2). Given that there is limited literature on SNPs in 
neurotransmitter systems that may be associated with psychosis in AD, the SNPs that we 
selected have previously been reported to be implicated in the development of psychotic 
symptoms in other neurodegenerative or psychiatric disorders, associated with AD, and/or 
to have functional consequences on transcript or protein levels. SNP data were recoded 
into disjunctive format prior to additional analyses. Using this format, each SNP was 
treated as a categorical variable with three levels (i.e. homozygous dominant, 
heterozygous, homozygous recessive). The advantages of coding SNPs using this 
genotypic model have been outlined previously in Beaton, Dunlop, & Abdi (2015)139, and 
include being able to assess the contribution of different alleles and genotypes to 
observed phenotypic traits or behaviours. This is particularly important because the minor 
or major allele coding scheme is often subjective and based on a particular cohort of 
participants. As such, what is coded as the major or minor allele in one study may vary 
across studies with different samples of participants. Using the genotypic model therefore 
22 
 
allows us to treat each genotype as a categorical variable and investigate the unique 
contribution of each genotype using a more general approach. To ensure that we were 
sufficiently powered to assess the effects of different alleles/genotypes, homozygous 
recessive genotypes with frequencies < 5%, were combined with heterozygous genotypes 
to form one category (?a). This second grouping encompassed individuals with both the 




























Table 1. Candidate single nucleotide polymorphisms (SNPs) in the Cholinergic (BCHE, 
CHRNA7) and the Dopaminergic (COMT, DRD1, DRD2, DRD3) neurotransmitter 
systems. 




Darvesh, Hopkins & 
Geula., (2003)140 
 
Yoo et al., (2014)141 
• BCHE – K variant has reduced 
catalytic activity, about 30% of 
the usual BChE 
• BCHE-K protects against 
pathology of AD that affects 
frontal cortical thickness and 
neuropsychiatric symptoms 
Cholinergic Receptor, 
Nicotinic Alpha 7 
Subunit 
(CHRNA7) 
15 rs6494223 Carson et al., (2008)100 
• Frequency of delusional 
symptoms was higher in 
patients homozygous for the T 





22 rs4680 Rosa et al., (2004)142 
• Val carriers have high enzyme 
activity, may have reduced 
dopamine levels in the 
prefrontal cortex, leading to 
decrease in D1 receptors 
activation 
• Can lead to impairment in 
working memory 
Dopamine Receptor D1 
(DRD1) 
5 rs686 Huang et al., (2008)143 
• G allele of rs686 decreases the 
levels of DRD1 expression by 
inhibiting the binding of 
microRNA miR-504 to the 
DRD1 3′-UTR   
Dopamine Receptor D2 
(DRD2) 
11 rs6277 Duan et al., (2003)144 
• Reported 50% of the time, 
957C>T, decreased DRD2 
mRNA stability and translation 
and reduced dopamine-
induced-up-regulation of 
DRD2 membrane expression in 
vitro   
• Alters the folding of the 
mRNA, mRNA is less stable 
which leads to markedly 
reduced protein synthesis rates 
Dopamine Receptor D2 
(DRD2) 
11 rs1076560 
Bertolino et al., 
(2009)145 
• Intronic SNP rs1076560 
strongly associated with D2 
short isoform/D2 long isoform 
ratios with GG schizophrenia 
subjects showing a higher 
percentage of the D2 short 
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isoform mRNA in prefrontal 
cortex than GT subjects 
Dopamine Receptor D2 
(DRD2) 
11 rs1800497 Makoff et al., (2000)146 
• C allele is a risk factor for 
hallucinations. This finding 
was found to be clinically 
significant in context of 
advanced neurodegeneration of 
chronic PD 
Dopamine Receptor D3 
(DRD3) 
3 rs6280 Savitz et al., (2013)147 
• Only known polymorphism that 
alters protein structure in this 
gene 
• Glycine allele yields D3 
autoreceptors that have a higher 
affinity for DA and display 


















Table 2. Candidate single nucleotide polymorphisms (SNPs) in the Glutamatergic 
(GRIN2A, GRIN2B, GRIN3A, GRIN3B) neurotransmitter system. 
 
Gene Chromosome SNP Literature Summary Key Findings 
Glutamate Ionotropic 
Receptor NMDA Type 





• Minor homozygote associated 
with the development of 
schizophrenia (OR=1.06) 
Glutamate Ionotropic 
Receptor NMDA Type 
Subunit 2B (GRIN2B) 
12 rs1805502 Weickert et al., (2013)149 
• NR1 and NR2C mRNA 
decreased in post-mortem brain 
analysis of those with 
schizophrenia 
• Found that the expression of 
NR1 subunit mRNA was 
significantly reduced in patients 
with schizophrenia who were C 
carriers of the SNP rs1805502 




Receptor NMDA Type 
Subunit 2B (GRIN2B) 
12 rs1806201 Andreoli et al., (2014)150 
• Significant contribution from the 
GRIN2B rs1806201 T allele 
towards Alzheimer’s disease 
susceptibility (adjusted odds ratio 
(OR=1.92, (95%CI: 1.40–2.63)) 
Glutamate Ionotropic 
Receptor NMDA Type 
Subunit 2B 
(GRIN2B) 
12 rs10845840 Stein et al., (2010)115 
• Risk alleles for lower temporal 
lobe volume at this SNP were 
significantly over-represented in 
AD and MCI subjects versus 
controls (OR=1.27; p =.039) 
Glutamate Ionotropic 
Receptor NMDA Type 
Subunit 3A 
(GRIN3A) 
9 rs3739722 Liu et al., (2009)151 
• Genetic variation of the NR3A, 
but not NR3B, subunit of the 
NMDA receptor may be a risk 
factor for AD pathogenesis 
among the Taiwanese population 
Glutamate Ionotropic 
Receptor NMDA Type 
Subunit 3A 
(GRIN3A) 
9 rs10989591 Gallinat et al., (2007)152 
• T,T individuals appeared to show 
better prefrontal information 
processing (higher frontal P300 
amplitudes), could reflect higher 
NMDA receptor efficacy 
Glutamate Ionotropic 





19 rs3764650 Karch et al., (2012)153 
• Minor allele associated with a 





2.7 Statistical Analysis 
Independent samples t-tests were used to compare age, years of education, MMSE total 
score and CDR global score for participants endorsing psychotic symptoms of interest 
and control groups. For the comparison of multiple cohorts of participants with psychotic 
symptoms, a Kruskal-Wallis test was used to determine group differences. Chi-square 
tests were used to compare the two groups on sex distribution, number of ApoE4 alleles, 
and scanner strength (1.5T vs. 3T).  
2.7.1 Partial Least Squares Correspondence Analysis: Overview 
Partial least squares correspondence analysis (PLS-CA) is a multivariate analysis 
technique that is both a generalization of partial-least squares correlation (used in 
neuroimaging studies) and an extension of correspondence analysis (dimension reduction 
technique for categorical variables). This method was formalized by Beaton and 
colleagues and is extensively detailed in their paper 139. To summarize, unlike traditional 
PLS, PLS-CA is able to simultaneously analyze two data sets that contain both 
continuous (i.e. neuroimaging) and categorical (i.e. genetic) variables. This process works 
through transforming continuous variables, like cortical thickness and subcortical volume 
measurements, into pseudo-categorical variables using an Escofier transformation. PLS-
CA uses generalized singular value decomposition to identify orthogonal pairs of 
underlying latent variables, with the first extracted pair explaining the greatest amount of 
covariance in the data sets. Non-parametric inferencing methods such as permutation and 
bootstrap resampling techniques are used to identify significant and stable components. 
With bootstrap confidence intervals, in particular, allowing for the post-hoc identification 
of group level differences. In addition, through the use of PLS-CA, we are able to treat 
SNPs as categorical variables, instead of as numeric based on the frequency of either the 
minor or major allele, thereby allowing us to examine how different SNP genotypes 
contribute to different effects within our sample. Overall, the PLS-CA approach can be 
used to identify global level interactions. These interactions can be inferred based on the 
latent factor and variable plots for each component. More specifically, ROIs and 
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genotypes that are in the same direction as one another, on the same component, can be 
inferred to be interacting together.  
2.7.2 PLS-CA 
Three independent PLS-CA were conducted to identify neuroanatomical and genetic 
correlates of delusions and hallucinations. The rationale behind separating the analyses 
into three different parts was to more closely examine the neuroanatomical and genetic 
interactions with increased power resulting from a larger sample size. This was achieved 
by first using a binary categorization scheme to identify interactions associated with the 
presence vs. absence of delusions and subsequently the neuroanatomical and genetic 
interactions associated with the presence vs. absence of hallucinations. The final analysis, 
which combined both of the aforementioned cohorts, was conducted to identify and parse 
any differences in neuroanatomical and genetic interactions for those with symptoms of 
hallucinations, delusions or both. 82 ROIs and 15 SNPs were included in the analysis. All 
cortical thickness and subcortical volume measurements were adjusted for participant 
age, sex, years of education, MMSE total score, CDR global score, number of ApoE4 
alleles, and scanner strength. To account for inter-individual differences in brain size, all 
subcortical volumes were also adjusted for total intracranial volume. Significance of each 
component was tested using 1000 permutations (p < 0.05). Significance of the variables 
contributing to each component was assessed using 1000 bootstrapped samples (bootstrap 
ratio > 2.0). Three different PLS-CA analyses were conducted with the subgroups 
categorized as follows: 
Analysis 1: Delusion Cohort (Binary Categorization). The first analysis categorized 
patients with AD/MCI into two groups based on the presence or absence of symptoms of 
delusions, irrespective of any other neuropsychiatric symptom. The two groups were 
categorized as follows: 1) AD patients who never endorsed symptoms of delusions 
throughout the duration of their ADNI visits (AD-D), and 2) AD or MCI patients who 
endorsed symptoms of delusions at their baseline ADNI visit or who developed 
symptoms of delusions over their disease course (AD+D) 
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Analysis 2: Hallucination Cohort (Binary Categorization). The second analysis 
categorized patients with AD/MCI into two groups based on the presence or absence of 
hallucinations, irrespective of any other neuropsychiatric symptom. The two groups were 
categorized as follows: 1) AD or MCI patients who never endorsed symptoms of 
hallucinations throughout the duration of their ADNI visits (AD – H), and 2) AD or MCI 
patients who endorsed symptoms of hallucinations at their baseline ADNI visit or who 
developed symptoms of hallucinations over their disease course (AD+H). 
Analysis 3: Combined Cohort (4 groups – to directly compare the interactions 
between brain regions and SNPs in those with AD+D, AD+H, AD+DH and AD-DH). 
The final analysis aggregated all patients with AD/MCI that had symptoms of 
hallucinations and delusions, or the absence of these symptoms, into one analysis. In this 
analysis, patients were categorized into four distinct groups: 1) AD patients who never 
endorsed symptoms of delusions or hallucinations throughout the duration of their ADNI 
visits (AD-DH); 2) AD or MCI patients who endorsed only symptoms of hallucinations at 
their baseline ADNI visit or who developed symptoms of hallucinations over their disease 
course (AD+H); 3) AD or MCI patients who endorsed only symptoms of delusions at 
their baseline ADNI visit or who developed symptoms of delusions over their disease 
course (AD+D), and 4) patients who endorsed symptoms of both delusions and 
hallucinations (AD+DH), at the identified ADNI visit.    
PLS-CA was conducted using R (Version 3.5.2) and the related statistic packages, 
ExPosition and TExPosition (Beaton, Chin Fatt, & Abdi 2014; Beaton, Rieck, Fatt, & 
Abdi, 2013), using the pipeline proposed in Beaton et al., 2015. 
2.7.3 Principal Component Analysis and Binary Logistic Regression  
To cross-validate brain regions identified by the PLS-CA, binary logistic regression 
analyses for all participants with available imaging data (irrespective of GWAS 
availability) were run for both the hallucination and delusion cohorts. Principal 
component analysis (PCA) with varimax rotation and Kaiser normalization was used as a 
dimension reduction technique to reduce the 82 ROIs into components. All cortical 
thickness and subcortical volumes for each ROI were transformed into Z-scores across 
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subjects prior to running the PCA. Following the PCA, the rotated component matrix was 
inspected and any components that did not have any ROIs that loaded most strongly to a 
particular component were excluded. The component scores for each retained component 
were then entered into binary logistic regression models with the dependent variable 
being either the presence/absence of delusions or the presence/absence of hallucinations. 
Additional covariates in the model included age, years of education, sex, CDR global 
score, MMSE total score, number of ApoE4 alleles and MRI scanner strength. Follow-up 
logistic regression models were run by removing any variables that were not significant in 
the prior model. Given the high degree of multicollinearity between ROIs in the identified 
components, post-hoc analysis of covariance (ANCOVA) with FDR correction was used 
to identify specific ROIs that may be contributing to the presence of 
hallucinations/delusions. 
PCA, binary logistic regression and post-hoc ANCOVAs were conducted using IBM 




































3.1 Imaging and Genetics: PLS-CA Results 
3.1.1 Delusion Cohort 
A total of 188 participants were identified from the ADNI-1 database as meeting the 
inclusion criteria. Of these, n=66 endorsed symptoms of delusions (AD+D), and n=122 
did not endorse symptoms of delusions (AD-D). Independent samples t-test comparing 
age, years of education, CDR global score, and MMSE total score, did not identify any 
significant differences between the two groups. Additional chi-square tests did not 
identify any group differences in sex distribution, MRI field strength, or number of 
ApoE4 alleles (Table 3). The minor allele frequencies for the 15 SNPs of interest were 
calculated for the entire cohort and are reported in Table 4. 
Results of the PLS-CA did not identify any significant differences in interactions between 
ROIs and SNPs that separated those with delusions from those without (Omnibus: p perm = 
.118, Component 1: p perm = .161). Despite not reaching the threshold for significance, 
Component 1 explained 40.45% of the variance in the dataset (Figure 1A). Although not 
significant, the interaction of specific ROIs and SNPs that are more closely associated 
with the delusion cohort, are ROIs with cortical thickness values below the grand mean 
(ROIs below the horizontal axis in Figure 1B, see Table 5 for complete list of ROIs) and 









N = 66 
No Delusions 
(AD-D) 
N = 122 
   
 Mean (SD) Mean (SD) t p-value  
Age 75.94 6.6 76.07 7.1 0.1 .91  
Years of Education 15.18 2.9 15.16 3.1 -0.06 .96  
CDR Global Score 0.88 0.43 0.92 0.43 0.7 .51  
MMSE Total Score 22.67 4.5 21.47 4.3 -1.8 .075  
 Males Females Males Females Fischer's Exact Test (2-sided)  
Sex (%) 53.0 47.0 62.3 37.7 0.277  
MRI Field Strength 1.5T 3T 1.5T 3T Fischer's Exact Test (2-sided)  
 64 2 119 3 1.00  
 Delusions (AD+D) No Delusions (AD-D)  
Number of ApoE4 alleles 0 1 2 0 1 2 Pearson Chi-Square 
 22 31 13 41 58 23 .99 
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Delusion Cohort PLS-CA, N=188 
Gene SNP Minor Allele Minor Allele Frequency 
BCHE rs1803274 T 0.170 
CHRNA7 rs6494223 T 0.402 
COMT rs4680 A 0.484 
DRD1 rs686 G 0.359 
DRD2 rs1076560 A 0.830 
DRD2 rs1800497 A 0.221 
DRD2 rs6277 G 0.431 
DRD3 rs6280 C 0.370 
GRIN2A rs9922678 A 0.330 
GRIN2B rs10845840 T 0.492 
GRIN2B rs1805502 G 0.156 
GRIN2B rs1806201 A 0.338 
GRIN3A rs10989591 T 0.293 
GRIN3A rs3739722 T 0.100 
GRIN3B rs3764650 G 0.080 
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Delusion Cohort  








Figure 1A.  
Figure 1C.  
Figure 1. Delusion Cohort PLS-CA results. A. Component p-values and latent variable (LV) plot for Component 1. 
The horizontal axis represents the SNPs and the vertical axis represents the brain regions of interest. Ellipsoids indicate 
boot-strap confidence intervals (95%) B. Neuroimaging boot-strap regression results for Component 1 with blue bars 
indicating significant brain regions. Red dashed line indicates the threshold for significance (+2 and -2) C. Single 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Delusion Cohort − Brain BSR
Figure 1B.  
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Table 5. Delusion Cohort: Neuroimaging boot-strap regression, summary of ROIs with 
cortical thickness values below the grand mean for Component 1. 
  
Delusion Cohort - ROIs more closely associated with the delusion cohort 
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3.1.2 Hallucination Cohort 
A total of 117 participants were identified from the ADNI-1 database as meeting the 
inclusion criteria. Of these, n=36 endorsed symptoms of hallucinations (AD+H), and 
n=81 did not endorse symptoms of hallucinations (AD-H). Independent samples t-test 
comparing age, years of education, CDR global score, and MMSE total score, did not 
identify any significant differences between the two groups. Additional chi-square tests 
did not identify any group differences in sex distribution, MRI field strength, or number 
of ApoE4 alleles (Table 6). The minor allele frequencies for the 15 SNPs of interest were 
calculated for the entire cohort and are reported in Table 7. 
Results of the PLS-CA identified a trend towards significance for Component 1, with the 
interaction of ROIs and SNPs in Component 1 explaining 45.44% of the variance in the 
dataset (Omnibus: p perm = .049, Component 1: p perm = .059; Figure 2A). Boot strap 
analysis showed that cortical thickness and subcortical volumes below the grand mean for 
bilateral frontal regions, bilateral cingulate regions, bilateral temporal regions, bilateral 
fusiform, right entorhinal, left inferior parietal, right lingual, right precuneus, right insula, 
and right accumbens area (Figure 2B; see Table 8 for complete list of ROIs) were 
associated with the major homozygote of rs3764650 in GRIN3B, and the minor 
homozygote of rs9922678 in GRIN2A (Figure 2C).This pattern of brain structure and 
combination of SNPs was more closely associated with those with symptoms of 

















N = 81    
 Mean (SD) Mean (SD) t p-value  
Age 74.89 7.1 75.85 6.2 .74 .46  
Years of Education 14.56 3.1 15.44 2.9 1.5 .14  
CDR Global Score 1.28 0.61 1.12 0.33 -1.42 .16  
MMSE Total Score 20.22 5.4 20.77 4.4 .57 .57  
 Males Females Males Females Fischer's Exact Test (2-sided)  
Sex (%) 52.8 47.2 58.0 42.0 0.687  
MRI Field Strength 1.5T 3T 1.5T 3T Fischer's Exact Test (2-sided)  
 36 0 78 3 0.552  
 Hallucinations (AD+H) No Hallucinations (AD-H)  
Number of ApoE4 alleles 0 1 2 0 1 2 Pearson Chi-Square 
 10 21 5 25 39 17 .54 
 











Hallucination Cohort N = 117 
Gene SNP Minor Allele Minor Allele Frequency 
BCHE rs1803274 T 0.171 
CHRNA7 rs6494223 T 0.427 
COMT rs4680 A 0.483 
DRD1 rs686 G 0.371 
DRD2 rs1076560 A 0.171 
DRD2 rs1800497 A 0.235 
DRD2 rs6277 G 0.432 
DRD3 rs6280 C 0.346 
GRIN2A rs9922678 A 0.329 
GRIN2B rs10845840 C 0.470 
GRIN2B rs1805502 G 0.141 
GRIN2B rs1806201 A 0.350 
GRIN3A rs10989591 T 0.303 
GRIN3A rs3739722 T 0.120 

















Hallucination Cohort  
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hallucination Cohort − Brain BSR










































Hallucination Cohort − SNP BSR
Figure 2C.  
Figure 2. Hallucination Cohort PLS-CA results. A. Component p-values and latent variable (LV) plot for 
Component 1. The horizontal axis represents the SNPs and the vertical axis represents the brain regions of 
interest. Ellipsoids indicate boot-strap confidence intervals (95%) B. Neuroimaging boot-strap regression results 
for Component 1 with blue bars indicating significant cortical regions and red bars indicating significant 
subcortical regions. Red dashed line indicates the threshold for significance (+2 and -2) C. Single nucleotide 




Table 8. Hallucination Cohort: Neuroimaging boot-strap regression, summary of 



















Hallucination Cohort - Significant ROIs with cortical thickness and 
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3.1.3 Combined Cohort 
A total of 207 participants were identified from the ADNI-1 database as meeting the 
inclusion criteria. Of these, n=21 endorsed symptoms of hallucinations only (AD+H), 
n=54 endorsed symptoms of delusions only (AD+D), n=10 endorsed symptoms of both 
hallucinations and delusions (AD+DH), and n=116 did not endorse symptoms of 
hallucinations (AD-H). A Kruskal-Wallis test with Bonferroni correction of between 
group differences identified a significant difference in CDR global score between the 
groups, with the AD+H group having on average a greater CDR score (higher disease 
severity) than the AD+D group (p=.017). A significant difference was also identified for 
MMSE total scores, with the AD+H group having on average lower total scores on the 
MMSE than the AD+D group (p=.022). No significant between group differences were 
identified for the other cohorts of interest (Table 9). The minor allele frequencies for the 
15 SNPs of interest were calculated for the entire cohort and are reported in Table 10. 
Results of the PLS-CA identified a trend towards significance for Component 1 
(Omnibus: p perm = .057, Component 1: p perm = .071; Figure 3A), with the interaction of 
ROIs and SNPs in Component 1 explaining 44.16% of the variance in the dataset. (Figure 
3A). Boot strap analysis showed that cortical thickness values below the grand mean for a 
number of bilateral frontal regions, bilateral temporal regions, bilateral parietal regions, 
bilateral fusiform, right entorhinal, left isthmus cingulate, left posterior cingulate, bilateral 
precuneus, right cuneus, left lingual, bilateral lateral occipital, and bilateral insula (Figure 
3B; see Table 11 for complete list of ROIs), were associated with the major homozygotes 
of rs3764650 in GRIN3B and rs1803274 in BCHE, the minor homozygote/heterozygote 
of rs1805502 in GRIN2B, and with the minor homozygote of rs9922678 in GRIN2A 
(Figure 3C). This pattern of brain structure and combination of genotypes was more 
closely associated with the AD+DH group than with any other group. In contrast, cortical 
thickness values above the grand mean for the aforementioned ROIs were more closely 
associated with the major homozygote of rs1805502 in GRIN2B, the minor 
homozygote/heterozygote of rs3764650 in GRIN3B, and the minor 
homozygote/heterozygote of rs1803274 in BCHE. Moreover, this pattern of brain 
structure and combination of genotypes was more closely associated with the AD+H 













































































Combined Cohort PLS-CA, N=201 
Gene SNP Minor Allele Minor Allele Frequency 
BCHE rs1803274 T 0.177 
CHRNA7 rs6494223 T 0.415 
COMT rs4680 A 0.485 
DRD1 rs686 G 0.363 
DRD2 rs1076560 A 0.167 
DRD2 rs1800497 A 0.213 
DRD2 rs6277 G 0.430 
DRD3 rs6280 C 0.356 
GRIN2A rs9922678 A 0.324 
GRIN2B rs10845840 C 0.495 
GRIN2B rs1805502 G 0.152 
GRIN2B rs1806201 A 0.326 
GRIN3A rs10989591 T 0.286 
GRIN3A rs3739722 T 0.102 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Combined Cohort − Brain BSR
Figure 3B.  Figure 3C.  
Figure 3. Combined Cohort PLS-CA results. A. Component p-values and latent variable (LV) plot for Component 1. 
The horizontal axis represents the SNPs and the vertical axis represents the brain regions of interest. Ellipsoids 
indicate boot-strap confidence intervals (95%) B. Neuroimaging boot-strap regression results for Component 1 with 
blue bars indicating significant brain regions. Red dashed line indicates the threshold for significance (+2 and -2) C. 





Table 11. Combined Cohort: Neuroimaging boot-strap regression, summary of 



































3.2 Neuroimaging Only Analysis 
3.2.1 Delusion Cohort 
A total of 363 participants were identified from the ADNI database as meeting the 
inclusion criteria. Of these, n=143 endorsed symptoms of delusions (AD+D), and n=220 
did not endorse symptoms of delusions (AD-D). Independent samples t-test comparing 
age, years of education, CDR global score, and MMSE total score identified a significant 
difference in MMSE total score between the two groups (p <.001), with the AD+D group 
on average having higher scores than the AD-D group. No significant differences were 
identified for any of the other covariates. Additional chi-square tests did not identify any 
group differences in sex distribution, MRI field strength, or number of ApoE4 alleles 
(Table 12). 
A principal component analysis was conducted on the z-scores of 82 regions of interest 
with orthogonal rotation (varimax). The Kaiser-Meyer-Olkin measure verified the 
sampling adequacy for the analysis, KMO = .95. The rotation converged in 11 iterations 
and 13 components were identified that had eigenvalues over Kaiser’s criterion of 1 and 
in combination explained 75.35% of the variance. The rotated component matrix was then 
used to identify ROIs that loaded most strongly to each component. No ROI loaded most 
strongly to component 12 and as such only components 1-11, 13 were retained for 
subsequent analyses. The 12 retained components reflected the following regions: 1) 
Bilateral frontal, parietal, occipital, and temporal, 2) bilateral orbitofrontal, middle 
frontal, frontal pole, orbitalis, 3) bilateral entorhinal cortex, amygdala, temporal pole, 
parahippocampal, insula, 4) left inferior, superior, middle, fusiform, isthmus cingulate, 5) 
bilateral caudal ACC, rostral ACC, posterior cingulate, right isthmus cingulate, 6) 
bilateral lingual, cuneus, pericalcarine, 7) right inferior temporal, superior temporal, 
middle temporal, fusiform, 8) bilateral pallidum, putamen, 9) bilateral caudate, 10) 
bilateral cerebellum, 11) bilateral thalamus, 13) bilateral accumbens area (Table 13). 
Component scores for each participant were also extracted for subsequent analyses. 
The initial logistic regression analysis included the component scores for the 12 
components described above in addition to the following covariates, age, sex, years of 
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education, CDR global score, MMSE total score, number of APOE4 alleles, and scanner 
strength. The overall model was significant χ2(20) = 33.01, p = .034. The model 
explained 11.8 % (Nagelkerke R2) of the variance in delusions and correctly classified 
66.9% of cases. The Wald criterion demonstrated that MMSE total scores (p= .004, 
Exp(B)=1.11 (95%CI: 1.04-1.20) made significant contributions to the presence of 
delusions. Trends towards significance were also identified for Component 2 (p= .068, 

































N = 143 
No Delusions 
(AD-D) 
N = 220    
 Mean (SD) Mean (SD) t p-value  
Age 74.80 7.2 75.94 7.3 1.5 .15  
Years of Education 15.31 3.0 15.18 2.8 -0.41 .69  
CDR Global Score 0.90 0.46 0.93 0.42 0.64 .52  
MMSE Total Score 22.94 4.3 21.28 4.2 -3.66 <.001  
 Males Females Males Females Fischer's Exact Test (2-sided)  
Sex (%) 52.4 47.6 58.6 41.4 0.279  
MRI Field Strength 1.5T 3T 1.5T 3T Fischer's Exact Test (2-sided)  
 89 54 150 70 0.259  
 Delusions (AD+D) No Delusions (AD-D)  
Number of ApoE4 alleles 0 1 2 0 1 2 Pearson Chi-Square 





FreeSurfer ROIs 1 2 3 4 5 6 7 8 9 10 11 12 13 
R Precentral 0.85                         
R Superior Parietal 0.83                         
R PostCentral 0.825                         
L Precentral 0.824                         
L Post Central 0.807                         
R Paracentral 0.803                         
R Caudal Middle Frontal 0.799 0.322                       
L Superior Parietal 0.795                         
L Paracentral 0.791                         
R Precuneus 0.79                         
R Supramarginal 0.77           0.383             
L Precuneus 0.767     0.362                   
L Caudal Middle Frontal 0.766 0.313   0.324                   
R Inferior Parietal 0.757           0.413             
L Superior Frontal 0.717 0.481                       
L Supramarginal 0.703     0.439                   
L Inferior Parietal 0.688     0.521                   
R Superior Frontal 0.677 0.555                       
R Lateral Occipital 0.615         0.472 0.306             
R Pars Opercularis 0.606 0.451                       
R Bank STS 0.601           0.482             
L Pars Opercularis 0.569 0.481                       
R Pars Triangularis 0.552 0.542                       
L Lateral Occipital 0.546     0.388   0.496               
L Transverse Temporal 0.48                     0.431   
R Transverse Temporal 0.447 0.303                   0.39   
R Lateral Orbitofrontal   0.746                       
L Lateral Orbitofrontal   0.719   0.3                   
L Pars Orbitalis   0.702                       
R Frontal Pole   0.702                       
L Frontal Pole   0.691                       
R Pars Orbitalis   0.682                       
R Rostral Middle Frontal 0.571 0.653                       
R Medial Orbitofrontal   0.652     0.304                 
L Medial Orbitofrontal   0.646     0.301                 
Table 13. Delusion Cohort: Rotated component matrix. Colours indicate ROIs loading most strongly to each 
component based on component scores. Loadings below 0.3 have been suppressed. R = Right, L=Left. 
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L Rostral Middle Frontal 0.562 0.645                       
L Pars Triangularis 0.472 0.552                       
L Entorhinal     0.791                     
R Entorhinal     0.761                     
R Amygdala     0.704                     
R Temporal Pole     0.692       0.336             
L Amygdala     0.689                     
L Temporal Pole     0.648 0.305               0.351   
L Parahippocampal     0.549   0.362                 
R Parahippocampal     0.541   0.356                 
R Insula   0.341 0.44   0.403   0.405             
L Inferior Temporal     0.32 0.712                   
L Middle Temporal 0.474     0.672                   
L Bank STS 0.524     0.589                   
L Fusiform 0.384   0.342 0.581                   
L Superior Temporal 0.452   0.384 0.488                   
L Isthmus Cingulate 0.388     0.4 0.382                 
L Caudal Anterior Cingulate         0.669                 
L Rostral Anterior Cingulate   0.331     0.651                 
R Caudal Anterior Cingulate         0.606                 
L Posterior Cingulate 0.454       0.579                 
R Posterior Cingulate 0.462       0.568                 
R Rostral Anterior Cingulate   0.361     0.495                 
R Isthmus Cingulate 0.323       0.495             -0.342   
L Insula 0.305 0.308 0.395 0.306 0.402                 
L Lingual 0.435     0.315   0.629               
R Cuneus 0.554         0.628               
R Lingual 0.458         0.615               
R Pericalcarine 0.512         0.611               
L Cuneus 0.517         0.597               
L Pericalcarine 0.518         0.566               
R Inferior Temporal 0.304   0.393       0.643             
R Middle Temporal 0.461   0.355       0.622             
R Superior Temporal 0.493   0.415       0.521             
R Fusiform 0.429   0.417       0.494             
L Pallidum               0.784           
R Pallidum               0.74           
R Putamen               0.636 0.509         



















L Caudate                 0.877         
R Caudate                 0.875         
R Cerebellum Cortex                   0.903       
L Cerebellum Cortex                   0.896       
R Thalamus                     0.901     
L Thalamus                     0.892     
L Accumbens Area                         0.801 
R Accumbens Area               0.419         0.581 
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3.2.1 Hallucination Cohort 
A total of 233 participants were identified from the ADNI database as meeting the 
inclusion criteria. Of these, n=84 endorsed symptoms of hallucinations (AD+H), and 
n=149 did not endorse symptoms of hallucination (AD-H). Independent samples t-test 
comparing age, years of education, CDR global score, and MMSE total score did not 
identify any significant differences between the two groups. Additional chi-square tests 
did not identify any group differences in sex distribution, MRI field strength, or number 
of ApoE4 alleles (Table 14). 
A principal component analysis was conducted on the z-scores of 82 regions of interest 
with orthogonal rotation (varimax). The Kaiser-Meyer-Olkin measure verified the 
sampling adequacy for the analysis, KMO = .94. The rotation converged in 12 iterations 
and 13 components were identified that had eigenvalues over Kaiser’s criterion of 1 and 
in combination explained 76.63% of the variance. The rotated component matrix was then 
used to identify ROIs that loaded most strongly to each component. No ROI loaded most 
strongly to component 13 and as such only the first 12 components were retained for 
subsequent analyses. The 12 retained components reflected the following regions: 1) 
bilateral frontal, parietal and occipital regions, 2) bilateral orbital frontal, middle frontal 
regions, 3) bilateral entorhinal cortex, amygdala, temporal poles, parahippocampal, 
insula, 4) left middle temporal, inferior temporal, superior temporal, fusiform, isthmus 
cingulate, 5) right superior, inferior and middle temporal, 6) bilateral lingual and right 
pericalcarine, 7) bilateral caudal ACC, left ACC, left posterior cingulate, 8) bilateral 
pallidum, putamen, 9) bilateral caudate, 10) bilateral cerebellum, 11) bilateral thalamus, 
12) bilateral accumbens area (Table 15). Component scores for each participant were also 
extracted for subsequent analyses. 
The initial logistic regression analysis included the component scores for the 12 
components described above in addition to the following covariates, age, sex, years of 
education, CDR global score, MMSE total score, number of APOE4 alleles, and scanner 
strength. The overall model was significant χ2(20) = 43.39 p = .002. The model explained 
23.3 % (Nagelkerke R2) of the variance in hallucinations and correctly classified 72.5% of 
cases. The Wald criterion demonstrated that Component 1 (p = .028, Exp(B) = 1.52 
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(95%CI: 1.05 - 2.20)), Component 2 (p=.012, Exp(B) = .644 (95%CI: 0.46 - 0.91)), 
Component 3 (p=.009, Exp(B) = 1.61 (95%CI: 1.13 – 2.29)), and Component 7 (p=.002, 
Exp(B)=.595 (95%CI: 0.43-0.83), made significant contributions to the presence of 
hallucinations. A follow-up logistic regression was conducted including only the 
variables that were identified as significant in the previous analysis. This included 
component scores for Components 1, 2, 3, 7. The overall model was significant χ2(4) = 
34.11, p < .001. The model explained 18.7% (Nagelkerke R2) of the variance in 
hallucinations and correctly classified 72.1% of cases. The Wald criterion demonstrated 
that Component 1 (p = .003, Exp(B) = 1.59 (95%CI: 1.18 - 2.12)), Component 2 (p=.024, 
Exp(B) = .699 (95%CI: 0.51 - 0.96)), and Component 3 (p=.001, Exp(B) = 1.67 (95%CI: 
1.23 – 2.25)), Component 7 (p=.003, Exp(B)=.622 (95%CI: 0.46-0.85), made significant 
contributions to the presence of hallucinations.. 
Post-hoc analysis of covariance with FDR correction (q<.010) compared the mean 
cortical thickness and subcortical volumes for ROIs loading most strongly to Components 
1, 2, 3, 7 between the AD+H and AD-H groups, with sex, age, years of education, CDR 
global score, and MMSE total score as covariates. Trends of larger cortical thickness 
were found for AD+H compared to AD-H in the following regions: left superior parietal 
(F(1,224)=4.31, p = .039, q = 0.307), left post central (F(1,224)=5.03, p =.026, q = .307), 
left cuneus (F(1,224)=4.1, p = .044, q = .307), left entorhinal (F(1,224)=6.5, p = .011, q = 
.055), right entorhinal (F(1,224)=6.9, p = .009, q = .055), left amygdala (F(1,224)=4.10, p 
= .044, q = .147). Trends for smaller cortical thickness for AD+H compared to AD-H 
were found in the following regions: left lateral orbitofrontal (F(1,224)=6.48, p = .012, q 
= .110), left medial orbitofrontal(F(1,224)=5.39 p = .021, q =. 110), right medial 
orbitofrontal (F(1,224)=4.7, p = .031, q = .116), and the right frontal pole (F(1,224)=5.32, 
p = .022, q = .110). Regions that were found to have significantly smaller cortical 
thickness values in AD+H subjects when compared to AD-H subjects included the left 
rostral anterior cingulate (F(1,224)=5.12, p = .025, q = .033), left caudal anterior 
cingulate (F(1,224)=10.25, p = .002, q = .004), and the right caudal anterior cingulate 























N = 149 
  
 
 Mean (SD) Mean (SD) t p-value  
Age 73.61 7.3 75.31 6.7 -1.8 0.07  
Years of Education 14.87 3.0 15.38 2.7 -1.3 0.19  
CDR Global Score 1.12 0.57 1.11 0.32 0.07 0.94  
MMSE Total Score 21.26 5.3 20.48 4.3 1.2 0.22  
 Males Females Males Females Fischer's Exact Test (2-sided)  
Sex (%) 52.4 47.6 54.4 45.6 0.786  
MRI Field Strength 1.5T 3T 1.5T 3T Fischer's Exact Test (2-sided)  
 50 34 104 45 0.116  
 Hallucinations (AD+H) No Hallucinations (AD-H)  
Number of ApoE4 alleles 0 1 2 0 1 2 Pearson Chi-Square 
 22 45 17 47 69 33 .552 
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Table 15. Hallucination Cohort: Rotated component matrix. Colours indicate ROIs 
loading most strongly to each component based on component scores. Loadings below 
0.3 have been suppressed. R = Right, L=Left 
 Components 
FreeSurfer ROIs 1 2 3 4 5 6 7 8 9 10 11 12 
R Superior Parietal 0.849                       
L Superior Parietal 0.837                       
R Precentral 0.825                       
R Precuneus 0.824                       
L Paracentral 0.818                       
L Precentral 0.818                       
R Paracentral 0.811                       
L PostCentral 0.804                       
R PostCentral 0.802                       
L Precuneus 0.779     0.34                 
R Caudal Middle Frontal 0.775 0.338                     
L Caudal Middle Frontal 0.773 0.337   0.365                 
R Inferior Parietal 0.772       0.405               
L Inferior Parietal 0.734     0.507                 
R Supramarginal 0.728       0.43               
L Supramarginal 0.705 0.325   0.433                 
L Superior Frontal 0.692 0.532                     
R Superior Frontal 0.671 0.577                     
R Cuneus 0.652         0.55             
R Lateral Occipital 0.642         0.433             
R Bank STS 0.607       0.529               
L Cuneus 0.598         0.513             
R Pars Opercularis 0.583 0.501                     
L Lateral Occipital 0.563     0.375   0.498             
L Pericalcarine 0.557         0.516             
R Fusiform 0.502   0.417   0.387               
R Posterior Cingulate 0.495 0.321         0.46           
L Transverse Temporal 0.445 0.377                     
R Isthmus Cingulate 0.388 0.382         0.333           
R Lateral Orbitofrontal   0.782                     
L Pars Orbitalis   0.781                     
L Lateral Orbitofrontal   0.745                     
R Pars Orbitalis   0.688                     
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R Rostral Middle Frontal 0.499 0.687                     
R Frontal Pole   0.687                     
L Medial Orbitofrontal   0.686         0.315           
L Rostral Middle Frontal 0.523 0.664                     
R Medial Orbitofrontal   0.653                     
L Frontal Pole   0.64                     
R Pars Triangularis 0.505 0.607                     
L Pars Triangularis 0.468 0.599                     
L Pars Opercularis 0.537 0.544   0.359                 
R Rostral Anterior Cingulate   0.488         0.348           
R Transverse Temporal 0.414 0.419     0.362               
L Entorhinal     0.765                   
R Entorhinal     0.756                   
R Temporal Pole   0.377 0.7                   
L Amygdala     0.698                   
R Amygdala     0.678                   
L Temporal Pole   0.387 0.611 0.31                 
R Parahippocampal 0.332   0.499                   
L Parahippocampal     0.492       0.36           
L Insula   0.415 0.422                   
R Insula   0.409 0.471   0.472   0.309           
L Inferior Temporal       0.721                 
L Middle Temporal 0.432 0.305   0.706                 
L Fusiform 0.404   0.331 0.579                 
L Bank STS 0.548     0.566                 
L Superior Temporal 0.407 0.34 0.33 0.542                 
L Isthmus Cingulate 0.378 0.308   0.495                 
R Superior Temporal 0.492   0.375   0.582               
R Middle Temporal 0.515   0.329   0.577               
R Inferior Temporal 0.389 0.325 0.381   0.542               
L Lingual 0.455     0.341   0.636             
R Pericalcarine 0.53         0.591             
R Lingual 0.524         0.571             
L Rostral Anterior Cingulate   0.365         0.713           
L Caudal Anterior Cingulate             0.699           
R Caudal Anterior Cingulate             0.522           
L Posterior Cingulate 0.48     0.316     0.489           
R Pallidum               0.763         


















R Putamen               0.608 0.451       
L Putamen               0.554 0.45     0.302 
L Caudate                 0.881       
R Caudate                 0.871       
L Cerebellum Cortex                   0.891     
R Cerebellum Cortex                   0.888     
R Thalamus                     0.854   
L Thalamus                     0.853   
L Accumbens Area                       0.712 
R Accumbens Area     0.325                 0.644 
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4.1 Discussion Overview 
The biological mechanisms underlying psychotic symptoms in AD are poorly understood. 
Some patients with AD develop psychotic symptoms early in their disease course while 
others remain asymptomatic throughout. The discrepancy between participants that 
present with psychotic symptoms and those that do not provides an opportunity to 
investigate differences between these two groups of AD patients. In particular, it allows 
us to compare differences in neuroanatomical structures and genetic variants that could 
potentially mediate the presence of these symptoms in AD. As such, in our study we 
sought to investigate if the interactions between regional brain changes and genetic 
polymorphisms in neurotransmitter systems may be associated with the presence of 
delusions and hallucinations in AD.  
Using PLS-CA we simultaneously assessed the interaction between 82 subcortical and 
cortical regions of interest and 15 SNPs in neurotransmitter systems to determine whether 
unique patterns of interactions may separate those with delusions, those with 
hallucinations, and those with both symptoms. Follow-up binary logistic regression 
analyses from a larger available sample were used to identify specific brain regions 
associated with the presence or absence of psychotic symptoms. For the delusion cohorts, 
results of the PLS-CA suggest that there are no significant interactions between 
neuroanatomical and genetic factors that distinguish those with delusions when compared 
to those without. In contrast, for the logistic regression analysis, although not significant 
we did identify a trend towards significance which suggests that cortical atrophy to 
orbitofrontal and middle frontal regions, coupled with relative preservation of temporal 
lobe structures may be associated with symptoms of delusions.  The results for the PLS-
CA for the hallucination cohort, suggest that individuals with AD and hallucinations may 
have a unique pattern of interactions in cortical regions and SNPs within the 
glutamatergic system when compared to those without hallucinations. Moreover, those 
with AD and symptoms of both delusions and hallucinations may have a distinct profile 
from those with just hallucinations even when matched for disease severity. Collectively, 
our findings suggest that delusions and hallucinations in AD may be associated with 
unique underlying neuroanatomic and genetic correlates and further highlight the 
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importance of investigating these as distinct symptoms of AD. These initial findings may 
also have implications for more specific and targeted treatment options for different 
psychotic symptoms in AD. 
4.2 Delusions in Alzheimer’s Disease 
To investigate differences between AD patients that presented with symptoms of 
delusions, we conducted two main analyses - PLS-CA and a binary logistic regression 
analysis. Participants with available neuroimaging and GWAS data who presented with 
symptoms of delusions and a control group of AD patients that did not, were included in 
the PLS-CA. The binary logistic regression analysis included a significantly larger cohort 
of participants that had structural imaging data, and unlike the PLS-CA was not limited 
by GWAS availability. An important limitation to note for the PLS-CA, was that most, if 
not all participants only completed the NPI-Q. The abbreviated questionnaire does not 
distinguish between specific subtypes of delusions in AD. This is particularly relevant 
because the two main subgroups – paranoid and misidentification delusions, may have 
unique underlying correlates 154. Moreover, delusions of theft, which are the most 
common subtype of delusions may be associated with memory impairments that arise as a 
result of AD. The lack of information with regards to specific subtypes of delusions that 
participants presented with may be a potential reason why we did not observe the 
hypothesized effects with regards to interactions between neuroanatomical and genetic 
factors.  
In contrast, the binary logistic regression analysis identified a trend towards significance 
for Components 2 and 3. Component 2 included frontal lobe structures such as bilateral 
middle and lateral orbitofrontal, pars orbitalis, and frontal poles. Component 3 consisted 
predominantly of temporal lobe structures including bilateral entorhinal cortex, amygdala, 
parahippocampal, temporal poles, and the right insula. In particular, lower component 
scores for Component 2 and higher component scores for Component 3 were associated 
with an increased risk for delusions. These findings suggest that cortical atrophy of 
frontal lobe structures and relative preservation of temporal lobe regions may be 
necessary to generate symptoms of delusions in AD. This finding is consistent with the 
hypofrontality model of delusions which postulates that impaired frontal lobe function, 
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either arising from atrophy or hypometabolism, may be associated with the presence of 
delusions in AD  57,155,156. In support of this model, a SPECT study of patients with AD 
and psychotic symptoms found that patients with delusions had hypoperfusion of the right 
frontal lobe when compared to those without delusions 66. While another, through the use 
of voxel-based morphometry, found that patients with AD and delusions when compared 
to those without delusions had smaller grey matter volumes in bilateral parahippocampal 
gyrus, right posterior cingulate, right orbitofrontal cortex, bilateral inferior frontal cortex, 
right anterior cingulate, and left insula 157. Although in our study we did not identify 
hemispheric lateralization with respect to delusional symptoms, the localization of these 
symptoms to the frontal lobe are consistent with prior studies. Furthermore, studies that 
directly assessed frontal lobe function through the use of cognitive rating scales found 
that psychotic symptoms in AD were associated with impaired working memory as 
measured by the digit span (forward and backward) task 158. One other study looking 
specifically at frontal lobe function in patients with AD and delusions also found that 
patients with AD and delusional thoughts had lower overall scores on the Frontal 
Assessment Battery when compared to those without symptoms of delusions 159. Based 
on the observed results, the authors hypothesized that impairments in executive 
functioning and not just episodic memory deficits may be associated with delusional 
thoughts. While the results of the binary logistic regression analysis showed a trend 
towards significance in frontal lobe regions, it may also be important to consider how 
other comorbid neuropsychiatric symptoms (i.e. depression, agitation, or apathy) may 
influence the presence of misidentification and paranoid delusions either through 
modulating attentional capacity or increasing susceptibility to paranoia. 
4.3 Hallucinations in Alzheimer’s Disease 
Results of the PLS-CA identified a trend towards significance for Component 1. In 
particular, the interaction between smaller cortical thickness values in a number of 
frontal, temporal, and parietal regions and SNPs in the glutamatergic system 
distinguished those with hallucinations from those without. The glutamatergic system has 
previously been implicated in the NMDA receptor hypofunctioning hypothesis of 
schizophrenia which postulates that downregulation of glutamate signaling in prefrontal 
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regions which project to subcortical structural such as the amygdala, nucleus accumbens, 
and brainstem structures may lead to the development of positive symptoms 160–162. More 
specifically, dysfunction in the cortical-brainstem circuitry arising from reduced 
glutamate signaling can lead to excessive dopamine release in the mesolimbic pathway, 
which can in turn result in hallucinations and delusions 163–165. A previous study has 
similarly implicated a role of the GRIN2A receptor, in particular identifying an 
association between the homozygous recessive genotype of rs9922678 in the GRIN2A 
receptor and a bilateral reduction in hippocampal volume in patients with schizophrenia 
166. This finding is in line with the results of the PLS-CA which suggest that the 
homozygous recessive genotype of res9922678 may be associated with reduced cortical 
thickness in temporal lobe structures. This finding further supports our rationale that 
regional brain atrophy arising from AD may unmask the effects of SNPs in 
neurotransmitters systems. This is particularly relevant to approved medications that are 
used to treat neuropsychiatric symptoms in AD, given that antagonism of the NMDA 
receptor may actually contribute to the development of hallucinations in patients with 
AD. For instance, Memantine is a non-competitive NMDA antagonist that is often 
administered to patients with AD. This drug was designed to treat glutamate neurotoxicity 
which arises as a result of excessive activation of glutamate receptors, which in turn can 
lead to neuronal death. Although Memantine has been shown to have some benefits on 
cognition and overall function, one of the most frequent documented side-effects of this 
drug includes hallucinations in patients with AD 167–169.  Given, the risk of hallucinations 
that are associated with Memantine, not only is it important to address whether these 
symptoms in AD are a result of the drug, but also the effect of this drug on patients with 
existing genetic variants in NMDA receptors. Namely, whether the frequency and 
severity of hallucinations may be exacerbated in patients with genetic variants in NMDA 
receptors. 
When considering the imaging data alone in the larger cohort, the logistic regression 
results were slightly different than the PLS-CA. In particular, the PLS-CA identified only 
regions that were smaller in those with hallucinations, while the binary logistic regression 
analyses identified regions with cortical thickness values that were larger and smaller in 
those with hallucinations when compared to those without. The main conflicting results 
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between the PLS-CA and binary logistic regression involved regions of the parietal lobe 
and the entorhinal cortex. Based on the PLS-CA these two regions were smaller in those 
with hallucinations when compared to controls, while in the binary logistic regression 
were larger in those with hallucinations, when compared to controls. The results of the 
binary logistic regression analysis suggest that larger cortical thickness in parietal, post-
central, amygdala, cuneus, and entorhinal cortex regions and smaller cortical thickness in 
the anterior cingulate may be associated with symptoms of hallucinations. One possibility 
as to why these differences may exist may be consistent with our initial prediction.  We 
posited that atrophy is necessary for unmasking the effects of SNPs, which may explain 
why the PLS-CA only identified ROIs that were atrophied in those with hallucinations 
when compared to those without. In contrast, the binary logistic regression analysis, 
which only looked at imaging variables in a larger sample, likely provides more 
information with regards to regions that are relatively preserved in those with 
hallucinations when compared to those without.  
The findings from the logistic regression are in line with some previous studies in patients 
with AD which suggest that relative preservation of parietal, temporal, and occipital 
regions are necessary for the generation of hallucinations 87. This particular pattern of 
frontal atrophy and preservation of temporal and posterior regions is also consistent with 
the case reports of Schneider and colleagues (1961), who noted that following localized 
lesions to the frontal lobe, patients who had suffered from previous falls or seizures 
developed hallucinations in the temporal and occipital lobes. The authors postulated that 
in this case abnormal activity was propagated along the uncinate fasiculus which connects 
frontal regions like the orbitofrontal cortex to temporal lobe and limbic structures 170. 
More specifically, it is thought that lesions in frontal regions which through the uncinate 
fasiculus are connected to temporal lobe structures important for visual recall may lead to 
abnormal firing from the frontal lobe to these temporal lobe structures to generate 
symptoms of visual hallucinations. In future studies of psychosis in AD it would be of 
interest to evaluate if those with a frontal-variant of AD would be more susceptible to 
hallucinations, and to assess white matter connectivity, particularly tracts connecting the 
frontal lobes to the parietal and temporal regions.  
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The anterior cingulate itself also plays a key role in self-referential processing and 
discriminating between self-generated and external information and has been implicated 
in the generation of hallucinations in schizophrenia 171,172. A SPECT study of psychotic 
symptoms in AD, also found that those with psychosis had lower regional perfusion in 
frontal regions such as the dorsolateral frontal, anterior cingulate, as well as other parietal 
and subcortical structures 173. Given the role of the anterior cingulate, we suggest that 
atrophy of the anterior cingulate, which we identified in our study, may result in 
misattribution of external stimuli to internal states thereby resulting in symptoms of 
hallucinations. Importantly, the anterior cingulate also has extensive connections to 
limbic structures,  including the amygdala and the insula, and has also been shown to be 
associated with the processing of negative emotions such as fear 174,175. When tying this 
back to hallucination in AD, abnormal perceptions generated from inaccurate internal 
representation of stimuli may lead to an increased fear response, and distress in those 
experiencing hallucinations. This is particularly important given that this may be a 
contributing factor to the increased rates of institutionalization of patients with AD and 
hallucinations 82,83. 
4.4 The Co-occurrence of Delusions and Hallucinations in 
Alzheimer’s Disease 
To investigate differences in patients with only delusions, only hallucinations, both 
hallucinations and delusions, and patients with neither symptom, we conducted a PLS-
CA. The objective of this analysis was to try and identify differences that may exist on a 
neuroanatomical and genetic level, between individuals who present with particular or 
multiple symptoms of psychosis. Results of the PLS-CA identified a trend towards 
significance for Component 1. Namely, the latent factor plot and bootstrap confidence 
intervals suggest that those with hallucinations only (AD+H) and those with both 
delusions and hallucinations (AD+DH) may have a unique pattern of interactions between 
SNPs and ROIs. Although it is difficult to draw definitive conclusions given the small 
cohort sizes, multiple comorbid psychotic symptoms may be associated with more 
advanced cortical atrophy or simply a different pattern of cortical reorganization in 
response to the cognitive deficits that arise from AD. Given the results of our study which 
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suggest that patients with AD+DH have cortical thickness values below the grand mean 
in the large majority of ROIs when compared to those with just hallucinations, we 
speculate that disease severity may be driving the observed differences between the two 
groups. One study that looked into the frequency of neuropsychiatric symptoms and AD 
found an association between increasing frequency of delusions, hallucinations and 
aberrant motor activity with increased disease severity 176. Although in our study the two 
groups did not differ in disease severity, it could be that those with AD+DH, while having 
more severe cortical atrophy, either have a different pattern of cortical reorganization or 
are able to use alternative compensatory cognitive strategies which may mask the degree 
of cognitive decline on clinical observation. Many studies that have described 
hallucinations in AD have tended to group together hallucinations and delusions into one 
overarching category of psychotic symptoms, which makes it difficult to parse underlying 
differences that may exist between the two. The findings of our study highlight the 
importance of investigating these symptoms as distinct phenomenon given the differences 
that we identified in the AD+H and AD+DH cohorts.  
4.5 Limitations and Future Directions 
This study was limited by the small sample size of participants endorsing symptoms of 
hallucinations and delusions. A replication cohort, potentially using individuals from the 
ADNI-2 database, may allow us to draw more definitive conclusions about the different 
interactions between brain regions and SNPs that may be associated with delusions and 
hallucinations. Furthermore, because many of the SNPs that we investigated were 
localized on the same chromosome, a haplotype analysis to detect SNPs that are in high 
linkage disequilibrium (more likely to be inherited together), may allow us to reduce the 
number of SNPs in our model and thereby increase the power of our study to detect 
associations between brain regions and genetic factors. In future studies, where we are 
powered to investigate more SNPs, it may be interesting to consider the interaction of 
neuroanatomical factors and SNPs in the serotonergic system. A previous study 
investigating the neuropathological and neurochemical correlates of psychosis in patients 
with AD, found that on post-mortem analysis, patients with psychotic symptoms had 
significantly reduced levels of serotonin in the prosubiculum and trends towards 
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reduction of serotonin in middle frontal, temporal, entorhinal cortex, and hippocampal 
regions 73. Additional information with regards to SNPs in the serotonergic system that 
may be interacting with different brain regions may be of particular interest when 
considering the effects of newer antipsychotic treatments in patients with AD. For 
example, a newer drug by the name of Pimavanserin, a 5-HT2A inverse agonist, has been 
approved in the United States for the treatment of hallucinations in patients with 
Parkinson’s disease. This drug is now also being tested for efficacy in patients with 
psychotic symptoms in AD. Early animal studies of this drug on psychotic symptoms in 
rodent models of AD, found that administration of Pimavanserin reduced psychosis-
associated behaviours such as head twitches, excessive locomotor activity, and also 
normalized pre-pulse inhibition 177. More recent human studies, including a randomized, 
double-blind, placebo controlled study investigating the efficacy of Pimavanserin in AD 
patients with hallucinations and/or delusions found that patients on the drug demonstrated 
significant improvements in psychotic symptoms when compared to those on placebo and 
did not experiences negative cognitive effects 178. Given these findings, looking 
specifically at SNPs in the 5HT2A receptor and their interaction with SNPs in other 
neurotransmitter systems and brain regions, could provide us with more information on 
the specific mechanism by which hallucinations and delusions arise in patients with AD.  
Furthermore, this study was limited because we were unable to dissociate between the 
specific subtypes of hallucinations and delusions within our cohorts. In future studies, 
where we are able to distinguish between the subgroups, it may provide us with more 
valuable information with regards to what particular subtypes of delusions or 
hallucinations may be driving the results that we obtained in our analysis. Given our 
findings of frontal lobe atrophy in patients with AD as well as frontal involvement in 
patients with hallucinations, in future studies it may be important to more specifically 
examine regions of hyper- and hypometabolism using fluorodeoxyglucose positron 
emission tomography (FDG-PET). This is because MRI data is limited in detecting only 
structural changes arising from regional cortical atrophy, which itself may not be easily 
identified in earlier stages of AD. FDG-PET may be a more powerful tool in detecting 
brain regions or networks that are abnormally hyper or hypo-active in response to 
disrupted cortical signaling. This in turn, may allow us to better understand the cortical 
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networks implicated in aberrant local and network-wide signaling which may give rise to 
symptoms of hallucinations and delusions in AD. Identifying networks of brain regions 
may then further guide diffusion tensor imaging studies to map white matter tracts that 
may be implicated in the pathology of psychotic symptoms in AD. This will allow us to 
better understand whether localized lesions to specific brain regions and/or connections 
between brain regions may be associated with AD+P. 
5 Conclusions  
In summary, the results of our study provide preliminary evidence of a unique signature 
of neuroimaging and genetic interactions which may be associated with the presence of 
hallucinations in AD. Specifically, these results suggest that genetic variants in the 
glutamatergic system, along with regional brain changes, may uniquely identify those 
with hallucinations. Although the results of the PLS-CA did not identify any significant 
differences in interactions between SNPs and ROIs, we did identify a trend towards 
significance in the logistic regression analysis which suggests that atrophy to the frontal 
lobe coupled with preservation of temporal lobe structures may be associated with 
symptoms of delusions in patients with AD. These findings further suggest that there may 
be distinct patterns of interactions that separate those with specific psychotic symptoms in 
AD from those without. Overall, knowledge of the interactions between SNPs in 
neurotransmitter systems and particular brain regions, may be an important starting point 
for earlier detection of those who may be susceptible to these symptoms in AD, and may 





Appendix A. Complete list of regions of interest included in analyses 
List of 82 Regions of Interest 
ST110TA Right Precentral ST130TA Right Insula 
ST51TA Left Precentral ST111TA Right Precuneus 
ST74TA Right Caudal Middle Frontal ST52TA Left Precuneus 
ST15TA Left Caudal Middle Frontal ST104TA Right Pars Opercularis 
ST115TA Right Superior Frontal ST62TA Left Transverse Temporal 
ST56TA Left Superior Frontal ST121TA Right Transverse Temporal 
ST84TA Right Frontal Pole ST72TA Right Bank Superior Temporal Sulcus 
ST98TA Right Medial Orbitofrontal ST36TA Left Lateral Orbitofrontal 
ST114TA Right Rostral Middle Frontal ST95TA Right Lateral Orbitofrontal 
ST55TA Left Rostral Middle Frontal ST46TA Left Pars Orbitalis 
ST25TA Left Frontal Pole ST105TA Right Pars Orbitalis 
ST39TA Left Medial Orbitofrontal ST106TA Right Pars Triangularis 
ST116TA Right Superior Parietal ST47TA Left Pars Triangularis 
ST108TA Right Post Central ST45TA Left Pars Opercularis 
ST102TA Right Paracentral ST13TA Left Bank Superior Temporal Sulcus 
ST57TA Left Superior Parietal ST34TA Left Isthmus Cingulate 
ST49TA Left Post Central ST24TA Left Entorhinal 
ST43TA Left Paracentral ST83TA Right Entorhinal 
ST118TA Right Supramarginal ST103TA Right Parahippocampal 
ST90TA Right Inferior Parietal ST44TA Left Parahippocampal 
ST59TA Left Supramarginal ST14TA Left Caudal Anterior Cingulate 
ST31TA Left Inferior Parietal ST73TA Right Caudal Anterior Cingulate 
ST32TA Left Inferior Temporal ST54TA Left Rostral Anterior Cingulate 
ST40TA Left Middle Temporal ST113TA Right Rostral Anterior Cingulate 
ST26TA Left Fusiform ST50TA Left Posterior Cingulate 
ST58TA Left Superior Temporal ST109TA Right Posterior Cingulate 
ST119TA Right Temporal Pole ST93TA Right Isthmus Cingulate 
ST60TA Left Temporal Pole ST53SV Left Putamen 
ST117TA Right Superior Temporal ST112SV Right Putamen 
ST91TA Right Inferior Temporal ST16SV Left Caudate 
ST99TA Right Middle Temporal ST75SV Right Caudate 
ST85TA Right Fusiform ST42SV Left Pallidum 
ST82TA Right Cuneus ST101SV Right Pallidum 
ST23TA Left Cuneus ST11SV Left Accumbens Area 
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ST107TA Right Pericalcarine ST70SV Right Accumbens Area 
ST48TA Left Pericalcarine ST12SV Left Amygdala 
ST97TA Right Lingual ST71SV Right Amygdala 
ST38TA Left Lingual ST61SV Left Thalamus 
ST35TA Left Lateral Occipital ST120SV Right Thalamus 
ST94TA Right Lateral Occipital ST17SV Left Cerebellum Cortex 
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